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Stereotactic Ablative Body Radiotherapy (SABR), when delivered to the lung, provides several
unique challenges from a quality assurance (QA) standpoint. To date, there has been little
research performed on the efficacy of QA at detecting significant dosimetric errors in organs
at risk (OARs). In addition, the feasibility of using the MapCHECK phantom housed in the
MapPHAN accessory for SABR QA is not fully appreciated. The aim of this study is to
investigate the sensitivity and specificity of MapCHECK in MapPHAN to introduced errors in
conformal arc SABR plans, with a specific focus on OAR dosimetry.
Multi-Leaf Collimator (MLC) class shift errors up to 2 mm, and isocentre shift errors up
to 1 mm, were introduced to 26 simulated 6 MV X-ray conformal arc lung SABR plans on
Raystation. 10 of these plans had errors introduced, and were delivered on a Varian Clinac iX
linear accelerator to the MapCHECK phantom housed in MapPHAN. In order to commission
the phantom for this project, the inherent angular dependency of the MapCHECK diodes had
to be corrected to within ± 2%. Gamma analysis was used to compare the measurements on
MapCHECK to the simulated Raystation plans, using 1%/1 mm, 2%/1 mm, 2%/2 mm, 3%/2
mm, 3%/3 mm and 5%/1 mm gamma criteria. Based on these results, Receiver Operating
Characteristic (ROC) curves were generated to determine the sensitivity and specificity of
MapCHECK in MapPHAN to the introduced errors. These ROC curves were then used to
determine an optimal set of gamma criteria for use in QA.
It was found that the angular dependency of the diodes in MapPHAN can be reduced to within
± 2% for the central section of the phantom, making it viable for absolute dosimetric measure-
ments of SABR plans. In general, the sensitivity and specificity of the phantom to introduced
errors was highest when using 5%/1 mm gamma criteria, although other criteria provided supe-
rior accuracy at certain gamma thresholds, with 2%/1 mm being the best alternative criteria.
The phantom was most sensitive to introduced MLC errors, and exhibited poor sensitivity and
specificity to introduced isocentre shift errors. This was exacerbated when automatic shifts
were introduced to correct for setup errors during gamma analysis.
In summary, MapCHECK in MapPHAN is a viable alternative to film for patient-specific
QA of lung SABR plans. It provides sufficient resolution to take measurements in high dose
gradient regions, and allows absolute dosimetry to be performed following angular dependency
i
corrections. Based on the results obtained here, a combination of 5%/1 mm with 95% threshold
and 2%/1 mm with 90% threshold would provide good sensitivity and specificity for QA of
conformal arc SABR plans. It is probable that placing restrictions on the shifts included in
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Lung cancer is the most prevalent form of malignant neoplasm in the world, and the leading
cancer-related cause of mortality worldwide [4, 5]. In New Zealand, lung cancer is the leading cause
of cancer-related mortality [6]; global statistics indicate that amongst females, New Zealand has one
of the highest rates of lung cancer worldwide [7]. In addition, the lung is one of the most common
sites for distant metastasis in many tumours. It has been estimated that almost one in three cancer
patients will develop pulmonary metastases during the course of their disease [8]. From geographic
and temporal analysis of lung cancer incidence worldwide, it is widely recognized that tobacco
smoking is the primary carcinogenic cause of lung cancer [4], with an estimated 85% of lung
cancer-related deaths caused by smoking [9]. It is likely that lung cancer will continue to be a
significant public health issue for decades to come [10].
1.2 Radiotherapy
Radiotherapy is one of the primary forms of treatment for lung cancer, along with surgery,
chemotherapy, and immunotherapy. It is defined as the medical delivery of ionising radiation to a
target volume of tissue, such as a cancerous lesion, with the aim of damaging or destroying said
1
2 Chapter 1. Introduction
tissue [11]. External beam radiation therapy (EBRT) is a form of radiotherapy in which the
radiation comes from a source external to the patient. Radiotherapy treatment plans are generated
on a Treatment Planning System (TPS), which is software designed for the planning and simulation
of these treatments.
1.2.1 Volume definitions
The International Commission on Radiation Units and Measurements (ICRU) has defined volumes
to standardize the delineation of different volumes of tissue in radiotherapy, in the recommendation
documents ICRU 50, 62 and 83 [1]. The Gross Tumour Volume (GTV) is used to define the gross
demonstrable extent and location of the tumour volume, as determined by the clinician. The Clinical
Target Volume (CTV) includes the GTV, along with all regions surrounding the GTV that have a
particular probability of containing unobservable cancerous tissue. An additional volume needs to be
considered for lung tumour treatments, since tumours typically follow a motion path that
corresponds to the patient’s breathing. The Internal Target Volume (ITV) is defined as the volume
that encompasses the CTV, accounting for fluctuations in the position, size and shape of the
volume [12]. The Planning Target Volume (PTV), in the context of lung tumour therapy, is a
geometrical concept introduced for the purposes of safe treatment planning. It is a volume contoured
in such a way as to shape dose distributions to ensure that the entire ITV (and by extension, CTV)
receives a dose above or equal to the prescribed dose. In general, a margin of error on the order of 5
millimetres is added to the ITV in all directions in order to account for errors that may be
introduced into the treatment process [12].
Any volumes of healthy tissue adjacent to the PTV are denoted as organs at risk (OARs). The aim
of a radiotherapy treatment is to deliver sufficient radiation dose to the target volume, while
minimizing the dose delivered to surrounding OARs as much as possible. To achieve this, the
oncologist will prescribe a certain dose level (measured in J kg-1, or Gray [Gy]) to be received by the
PTV. They will also recommend dose limits for the OARs.
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Figure 1.1: Planning volumes as denoted in the ICRU documents [1].
1.2.2 Linear accelerators
EBRT is typically delivered using a linear accelerator, or linac - a type of compact particle
accelerator, which uses a high voltage waveguide to accelerate electrons onto a tungsten target; the
resultant collisions with the target generates X-rays primarily by bremmstrahlung radiation [13].
Figure 1.2 indicates the main structures of which a linac is comprised. Electrons are produced via
thermionic emission from the cathode of the electron gun, which is supplied by pulses of power from
the pulsed modulator. At the same time, the modulator sends pulses on the order of 50 kV to the
radiofrequency power source, which is typically a magnetron (or in the case of high-power linacs, a
klystron), allowing the electrons to be accelerated by the waveguide [13]. The accelerating waveguide
has to be evacuated of air via vacuum pump, in order to increase the mean free path of electrons
within the waveguide to the point that the total electron path length is negligible by comparison.
Natural divergence of these electrons due to the radial component of the electric fields in the
waveguide is refocussed via the use of focusing coils in the waveguide, which produce a coaxial
magnetic field to generate a pencil beam of electrons. This is guided into the head of the linac using
bending magnets, typically configured to send the beam through a 270o arc before striking a target
made of tungsten. The interaction of the electron beam with the target produces bremsstrahlung
radiation and characteristic X-rays in the mega-voltage (MV) range of energies [13].
The structures housed within the linac head are attached to a gantry, which rotates around the
couch on which the patient lies, allowing for the delivery of radiation to the patient from multiple
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Figure 1.2: Schematic diagram of linear accelerator with waveguide mounted parallel to gantry
axis of rotation (not to scale). Taken from Rowshanfarzad [2].
angles. Hence positioning the target volume at the centre of the axis of rotation of the linac will
result in a high dose of radiotherapy being delivered to the tumour volume, and simultaneously
minimise the dose being delivered to adjacent healthy tissue. (It is common for gantry angle to be
denoted in shorthand. For instance, G230 means that the gantry is positioned at 230o.)
The linac head contains various structures that conform the beam to the target volume, allowing for
further reduction of dose to OAR’s. The primary collimator consists of a circular opening machined
into a tungsten block, defining a maximum circular field; this can then be further confined via use of
adjustable secondary collimators, consisting of two upper and two lower independent jaws which
truncate the beam into a rectangular field. Between the primary and secondary collimators lies a
flattening filter, which can be used to modify the beam output into a flat beam profile when
measured at the level of the patient.
Further beam collimation is achieved via use of a Multi-Leaf Collimator (MLC). In the case of the
Varian Clinac iX linear accelerator (Varian Medical Systems Inc., CA, U.S.A.), this is a series of 120
opposing tungsten leaves that sits behind the secondary collimating jaws of the linac. While the X-
and Y-jaws serve to define the overall field size of the beam, the MLC provides higher-resolution
collimation to conform the beam to the contours of the target volume. In treatments that utilise arc
therapy, the MLC’s leaves move in real-time to modulate the field shape as the gantry of the linac
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rotates. The position of the leaves at any point in the treatment is defined by a finite number of
control points, at a predefined interval - typically between 2-5o. An MLC-defined field shape is
optimised for each control point, with the MLC leaf position between each control point determined
via interpolation [14].
1.2.3 Interaction mechanisms of ionising radiation
Due to the high energies utilised to generate electrons in linacs - typically on the order of several
MeV - modern linacs primarily produce X-rays by means of bremmstrahlung radiation. This
phenomenon occurs when charged particles are accelerated by the electric field of an atomic nucleus.
The kinetic energy lost by the charged particle is converted to a photon, which is emitted [15]. In
the linac, the X-rays are generated in the tungsten target. The spatial distribution of X-rays around
the target is such that the vast majority of photons are emitted in the same direction as the original
electron beam [16].
The radiation dose absorbed by a volume of mass m is found by the relationship
D = δε/δm,
where ε is the sum of radiation energy entering the volume minus the energy leaving the volume,
measured in Gy [16].
The three major interaction processes that govern the dose delivered by megavoltage X-ray beams
are the photoelectric effect, Compton scattering, and pair production [16]. For X-ray beams
generated by 6 MeV electrons, the Compton effect will be dominant for most tissue densities,
although pair production becomes predominant at higher atomic numbers, as can be seen in Figure
1.3 [3].
1.2.4 Percentage depth dose curves
The radiation dose deposited as a function of depth in a medium can be graphically represented in
the form of a percentage depth dose (PDD) curve. An example of a PDD is shown in Figure 1.4.
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Figure 1.3: Regions of relative predominance for photoelectric effect, Compton effect, and pair
production in matter. The curves represent the lines of equality for the adjacent effect regions.
Modified from [3].
Several key regions can be observed in this figure. The region between z = 0 and z = Dmax (a depth
known as zmax) is known as the buildup region. The relative decrease in dose for this region is due to
the lack of charged particle equilibrium (CPE) at the surface of the patient. In this region, there are
fewer secondary charged particles due to the absence of medium above the surface [17]. Hence at this
point, the electron fluence is less than the equilibrium fluence of secondary charged particles
established in the surrounding medium. CPE, where the number of electrons entering a volume is
the same as that exiting the volume, is established at zmax, where z is approximately equal to the
mean range of the secondary charged particles, and the condition of fluence equilibrium is attained.
Beyond Zmax, transcient CPE occurs due to photon attenuation and scattering in the medium [17].
The rate of dose decay in the medium then becomes approximately proportional to the inverse
square law as the distance from the source increases, while also being a function of the attenuation
constants of the medium placed in the beam path [18].
When performing dosimetry, it is recommended to avoid measuring dose in the buildup region of the
PDD, for several reasons. Electron contamination from the linac head is typically limited to shallow
depths below zmax, due to the high rate of attenuation of low energy electrons in water. This,
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Figure 1.4: PDD for a 6 MV flattened X-ray beam in water, showing features such as the
buildup region prior to Dmax at an approximate depth of 1.5 cm, and exponential falloff at
depth.
coupled with the lack of CPE in the region, increases the uncertainty in the electron dose for the
buildup region. Placing the dosimeter at depths beyond zmax negates this issue, although the use of
an extrapolation chamber is an alternative solution [19,20]. The relatively high dose gradient in this
region is another factor, since this increases the potential for geometric setup inaccuracies to increase
the uncertainty in measured dose [20].
1.3 Radiobiology
Radiobiology is the study of the effects of ionizing radiation on cells. It covers a broad range of
topics, from the effects of different types of radiation on cellular biology, to the effects of different
types of DNA damage over varying timescales.
For every Gray of absorbed radiation dose, a cell of diameter 10 µm will experience at least 105
ionization events within its volume [21]. These ionization events generate free radicals, which are
highly reactive and cause substantive chemical damage to the cell. Some of these lesions are
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generated in DNA; most of these are then repaired by the cell. The DNA breakages that fail to
repair may eventuate in cell death. While the chemical reactions that generate these DNA breakages
are typically complete within approximately 1 ms of radiation exposure, the effects of the damage
may be observed up to several years after the exposure [21].
1.3.1 Cell survival curves
The rate of cell survival in an irradiated volume of tissue can be expressed with some accuracy using
the linear-quadratic model, which assumes that there are two components to cell kill via radiation -
α, which denotes the component of cell death that is proportional to dose, and β, which denotes the
component that is proportional to the square of the dose. The cell survival fraction (S) for a
delivered dose (D) is given by:
S = exp−αD−βD
2
where α and β are constants with units of Gy-1 and Gy-2 respectively [22]. It is common practice to
define a constant called the α/β ratio, which defines the dose in Gy at which the two components
contribute equally to cell kill [23].
α and β have been experimentally determined to varying levels in the vast majority of human
tissues. By comparing the α/β ratio for tumour tissue to that for healthy tissues which also receive
dose during treatment, one can determine what fractionation scheme will produce the most beneficial
treatment outcome for that particular tumour-tissue combination [24]. For instance, tissues can
generally be classified as either ’early responding’, in that they are damaged quickly by radiotherapy
but can be spared by prolonging of treatment; or ’late responding’, in that they respond more slowly
but at a more linearly proportional rate to radiation dose [23]. More simply put, prolonging the
treatment time of radiotherapy has the greatest sparing effect on early responding tissues.
Figure 1.5 shows a typical survival curve for early and late responding tissues. As can be seen in the
equation above, α comprises the linear portion of the survival curve, whereas β comprises the
quadratic portion, which gives the function some curvature. Hence it can be deduced that early
responding tissues have a high α/β ratio, while late responding tissues have a low α/β ratio [24].
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Figure 1.5: Example of surviving fraction for early and late responding tissues. Early respond-
ing tissues have a high α/β ratio, while late responding tissues have a low α/β ratio.
1.3.2 Fractionation
Since ionising radiation is absorbed by both the target tissue and healthy tissue during radiotherapy,
it is necessary to plan the treatment in such a way as to minimise the damage to healthy tissue while
maximising the volume of cancerous tissue that is destroyed. The therapeutic success of such a plan
depends on the estimated balance of tumour control probability (TCP) and normal tissue
complication probability (NTCP) that arises from the dose distribution within the patient. It also
depends on the schedule with which the dose is delivered over time, also known as
fractionation [25,26].
Fractionation is necessary because current techniques are unable to generate a dose distribution for a
single fraction that is sufficiently conformal for sparing of healthy tissues surrounding the target
volume, while delivering a sufficiently ablative dose to the CTV. The division of a single ablative
dose into multiple fractions of partially ablative doses spread out over a specified period of days
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allows healthy tissue to repair in between fractions. However, this scheme also allows cancerous
tissue time to heal in between fractions, meaning that a higher overall dose must be delivered to the
tumour to provide an adequate rate of cell kill. The downside of this is an increased risk of
secondary tumour generation, as radiation (while useful for the immediate destruction of tissue) is
also a carcinogen, and an increase in radiation dose is associated with an increased risk of tumour
generation later in life [27].
Hypofractionation
A fractionation scheme with dose greater than 2 Gy per fraction (considered to be the conventional
scheme) is termed hypofractionation [28]. However, the advancement of radiotherapeutic techniques,
equipment and treatment planning systems has significantly increased the conformality that can be
achieved with a planned dose distribution. Innovations such as the introduction of Intensity
Modulated Radiation Therapy (IMRT), which brought with it significant improvements in the
accuracy and manoeuvrability of MLC leaves, have mitigated the risk of excessive toxicity in normal
tissues, bringing down the NTCP for these tissues while simultaneously enhancing the TCP value for
the tumour [28,29]. Additionally, trials such as CHART (Continuous Hyperfractionated Accelerated
Radiation Therapy) have shown that decreasing overall treatment time has significant benefit in
certain cases [30,31]. A typical hypofractionated scheme used for the treatment of non-small cell lung
cancers, for example, would be 48 Gy delivered to the volume in 4 fractions, or 12 Gy per fraction.
Hypofractionation is not an optimal treatment solution for all cancers. For example, the α/β ratio is
higher in brain tumours than in brain tissue, meaning that hyperfractionation is required to
maximize the therapeutic ratio for radiotherapy of the brain. However, for cancers such as those
found in the prostate and lung, the reverse is true: the α/β ratio is lower in the tumour than in the
surrounding tissue. This allows clinicians to utilize hypofractionation, with the additional benefit of
the tumour being more sensitive to fraction size. The main risk of hypofractionation is the excessive
exposure of adjacent normal tissues to undesirable levels of toxicity, without enough time for
sublethal repair to occur [32]. For instance, a common side effect of delivering high doses of
radiotherapy to peripheral lung tumours is rib fracture, the risk of which is associated with tumour
location, volume and proximity. In addition, dose metrics such as V160, the volume of tumour
receiving greater than 160 Gy, and D4.6cc, the dose received by at least 4.6 cm
3 of the rib, can both
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be used to predict increased risk of fracture [33].
1.4 Stereotactic Ablative Body Radiotherapy
There are several distinct radiotherapy techniques that may be utilised for the treatment of lung
cancer. The technique being studied in this thesis is known as Stereotactic Ablative Body
Radiotherapy, or SABR (also known as Stereotactic Body Radiotherapy, or SBRT). SABR involves
the precisely targeted delivery of fewer fractions with a higher dose per fraction, utilising the α/β
ratios of certain types of tumour in order to maximise TCP and NTCP outcomes for a
treatment [29]. In terms of patient outcomes, SABR is considered to be one of the most effective
medical techniques available for treatment of non-small cell lung cancer [34–36].
Hypofractionation in SABR has been made possible in recent years by significant improvements in
kV and MV imaging technologies, allowing sub-millimetre setup accuracies to be achieved, with an
overall radiation delivery precision of 1-2 millimetres [37]. SABR utilises multiple coplanar and
non-coplanar beams guided by a rigid co-ordinate system with structures in place to immobilize the
patient, typically using image-guided alignment during treatment to enhance accuracy. Tumour
motion in the lung is normally compensated for with various immobilization, tracking, and gating
techniques, although this project focusses on the accuracy of radiotherapy delivered to a static
volume.
In order to treat deep-seated tumours surrounded by healthy tissue using EBRT, some ionising
radiation will need to pass through healthy tissue, depositing dose along the way. The use of higher
doses per fraction in SABR means that to deliver SABR safely using X-rays, one must plan the
treatment in such a way as to spread the necessary dose to OARs over a greater volume of healthy
tissue. Hence, one must use either multiple fields (e.g., 10 or more) or large angle arc rotations with
small aperture fields, in order to limit exposure to normal tissue [29].
Non-small cell lung cancer is an example of a tumour in which the α/β ratios for the tumour and
surrounding normal tissues are suitable for hypofractionation [38,39]. Tumours in the lung are
surrounded by three critical organs - namely the heart, lung and spinal cord - and the management
of dose to these tissues is second only to PTV coverage in terms of importance in the treatment
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planning process. Treating with SABR provides a conformal dose distribution with sufficient
accuracy to generate an ablative dose to small tumours while sparing significant lung volume from
excess radiation. The high dose gradients provided by SABR are especially useful for the treatment
of central tumours close to the heart and spine, where the separation between the treatment volume
and critical structures is too small for conventional radiotherapy to be successful [38,40].
1.5 Treatment planning
The introduction of the computerised TPS led to rapid innovations in treatment planning. The TPS
stores beam model data for simulating dose distributions in media, based on input parameters set by
the user. During the commissioning process for a linac, this beam model data is calculated and
measured for every combination of beam type and beam energy that the linac is capable of
producing. As part of the beam model data, the standard calibration factor of the linac for each
beam energy is calculated with units of cGy per monitor unit (MU), allowing the dose for each
patient’s treatment plan to be calculated as a certain number of MU’s [16]. Using this value, the
beam output of the linac may then be monitored by the ionization chambers located in the linac
head, as an additional safety measure. The chamber’s electrometer circuitry is typically adjusted so
that 1 MU is equivalent to a dose of 1 cGy delivered to a water phantom at the depth of maximum
dose on the central beam axis, using a 10 x 10 cm2 field at a source-to-surface distance of 100 cm [16].
The most common treatment planning method still in use today is 3D conformal radiotherapy, or
3D-CRT. To optimise a 3D-CRT treatment, a planner will manually select appropriate beam angles
and weightings to create a conformal dose distribution, in a process known as forward planning.
This is essentially a trial-and-error approach to treatment planning [41]. In recent years, planning
has evolved to the extent that optimization via inverse planning is now possible, where dose
constraints are set initially and a computer optimizes the plan within human-set boundaries, via
Pareto-frontier optimization [41,42]. SABR itself can be planned with 3D-CRT, but may also be
planned with one of the methods detailed in the remainder of this Section, although each method
has its own set of strengths and weaknesses.
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1.5.1 Treatment setup parameters
Isocentre
The fixed point around which a body rotates in 3-dimensional space is known as the isocentre of
rotation for that body. The isocentre definition most relevant to treatment delivery is the radiation
isocentre, which has been defined according to Zhang et al. as follows. At any gantry angle, a
straight line between the X-ray source and centre of beam collimation (both functions of gantry
angle) can be drawn. The centre of the smallest sphere that is intersected by all of these lines is the
radiation isocentre [43]. This isocentre is separate from the mechanical isocentre, which has been
defined as ”the intersection point of the axis of rotation of the collimator and the axis of rotation of
the gantry” [43]. During the installation of a linac, lasers are set up in the treatment room in such a
way that their point of intersection is aligned with the machine isocentre. This intersection point is
then used as the primary reference point for patient localisation during treatment, with all couch
shifts performed relative to this point. The mechanical isocentre will never be perfectly aligned with
the radiation isocentre, due to various factors such as gantry sag (the effect of gravity on gantry
position), which can introduce errors on the order of a millimetre to the isocentric position [44].
1.5.2 Intensity Modulated Radiation Therapy
Intensity Modulated Radiation Therapy, or IMRT, is an inverse-planned radiotherapy technique. To
generate an IMRT plan, a TPS will use simulated annealing to find an optimal solution for field
apertures, beam directions, beam weights and MLC leaf positions, in order to achieve constraints set
by the planner [41]. Human guidance is necessary to set these constraints, so that the number of
Pareto-optimal solutions can be reduced in the interest of efficiency. The conformality that can be
achieved with multiple IMRT fields is superior to that attainable with 3D-CRT, with a significant
reduction in OAR doses made possible [41,45].
Volumetric Modulated Arc Therapy
Volumetric Modulated Arc Therapy (VMAT) is a type of IMRT, in which the gantry rotates
continuously during treatment delivery. It has a greater number of degrees of freedom than standard
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IMRT, as it permits the simultaneous variation of gantry rotation speed, MLC leaf position and dose
rate, while also reducing the number of MUs per fraction [14]. The plan is delivered in full 360o arcs,
which are divided into control points.
A comparison of treatment techniques indicates that IMRT and VMAT typically produce a
substantial reduction in the dose to OARs. [46,47]. Although VMAT can increase the total dose
received by normal tissues, it does have the advantage of spreading this dose over a greater volume
of tissue, which reduces the maximum dose (and thus the NTCP) for certain OARs [14].
1.5.3 Dynamic Conformal Arc Therapy
Dynamic Conformal Arc Therapy (DCAT) is similar to VMAT, in that the gantry rotates
continuously during treatment delivery. However, only MLC positions are modulated in DCAT, and
the dose rate remains continuous during the treatment. The MLC shape is defined by the shape of
the target volume, as seen through the beam’s eye view of the source (i.e. the source as viewed from
the virtual source of the linac, in the gantry head). Because of this, the MLC field size is generally
greater for DCAT treatments compared to VMAT. This can lead to less uniform PTV doses with
greater dose maximums than VMAT treatments, which is normally acceptable due to the high
ablative doses used in SABR [48].
VMAT is generally considered to be a more precise technique than DCAT, able to generate more
conformal dose distributions with lower OAR doses and more uniform PTV doses [49]. However,
since VMAT treatment plans uses MLC leaves to reduce OAR doses, the control points for these
plans regularly contain leaves that block the PTV. This increases the uncertainty in PTV dose
compared to conformal arc plans, due to factors such as the interplay effect, where the out-of-phase
interactions between MLC motion and target motion generates unpredictable differences between
planned and delivered doses [50]. This is especially an issue for lung treatments, where breathing
motion is significant compared to PTV size.
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1.5.4 Dose Volume Histograms
The Dose Volume Histogram (DVH) is a tool used by planners for volume-specific analysis of a
plan’s dosimetry. It summarizes the dose distribution information over a 3D matrix of points in the
patient’s anatomy. The most commonly used version is the cumulative DVH, an example of which is
shown in Figure 1.6, although there are alternatives to this, such as the differential DVH [25,51].
The main disadvantage of the DVH is the lack of spatial information provided by the graph, which
summarizes doses to each volume as a whole and hence does not provide any further information
about the dose at different points in the volume [51]. Hence the DVH cannot be used as a
standalone tool for plan analysis.
Figure 1.6 shows an example of a cumulative DVH for a lung SABR patient, over the entire course of
treatment. Several key metrics can be derived from this figure; for instance, it can be seen that the
maximum point dose being received by the PTV is approximately 60 Gy, while 95% of the PTV
volume is receiving a minimum dose of 49.31 Gy. These metrics can be used to define some tolerance
thresholds for the plan. In this case, the clinician may want to ensure that the spinal cord receives
no more than 18 Gy, since doses above 18 Gy have been associated with increased risk of
neurological deficits such as myelopathy [52]. Hence a limit may be placed on the maximum point
dose that can be received by the volume ’SpinalCord PRV’, which is the Planning Risk Volume for
the spinal cord (a volume containing the spinal cord contour, with an isometric 3 mm risk margin
added on all sides of the volume for additional safety). This constraint can then be used to optimize
the plan in such a way as to prevent the spinal cord dose from exceeding the tolerance dose.
1.6 Patient specific quality assurance
Quality assurance (QA) is an essential process in radiotherapy. One of the main roles of the medical
physicist is ensuring that treatment plans are being delivered to the highest possible standard of
conformality and quality. Patient-specific quality assurance (PSQA) is a branch of QA that involves
simulating the delivery of a treatment plan on the machine itself, then comparing the outcomes of
this treatment delivery to the predicted outcomes of the treatment plan. This is done to ensure the
treatment being delivered is consistent with the prescribed plan. The measurement of expected dose
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Figure 1.6: Example of a DVH for one of the lung SABR patients in this study, with overlaid
dose metrics. This DVH was generated in the Raystation TPS.
can be performed in several ways, some of which are discussed below.
1.6.1 Ionization chambers
The ionization chamber is the most commonly used dosimeter in radiotherapy. It typically consists
of an unsealed cavity of air encapsulated by a conducting electrode, with a collecting electrode at its
centre. Ionizing radiation passing through this cavity ionizes air within the chamber volume and
produces pairs of charged particles which are collected by the electrodes, producing a current which
is measured by a connected electrometer. The number of primary ions collected is proportional to
the energy deposited by the charged particle tracks in the detector volume, which can then be used
to calculate the dose delivered to the chamber. An example of a CC04 ionization chamber (IBA
Dosimetry, Louvain-La-Neuve, Belgium) used in this thesis is shown in Figure 1.7. The outer and
inner electrodes of this chamber consist of C-552 plastic, and house an active air volume of 0.04 cm3,
a volume small enough to be approximated as a point for the purpose of point dose measurements.
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Figure 1.7: Image of CC04 ionization chamber used during this thesis.
Radiochromic film
Radiochromic film is a near tissue-equivalent dosimeter that can be used to measure a 2D dose
distribution with extremely high resolution. It is approximately energy independent above 0.1 MeV,
making it ideal for measurement of high energy X-ray dose distributions. Absolute dosimetry is
possible following calibration of a batch of film, whereby multiple film pieces are irradiated at
different levels and scanned into a computer. The development of each piece of film can be used to
generate a calibration curve of film density (logarithm of opacity) versus the logarithm of exposure,
from which absolute dose can be calculated. The dose distribution in the film can then be compared
to the original calculated dose distribution [53].
Silicon diodes
With their small volume and high atomic number materials, diode detectors offer the advantage of
higher spatial resolution and sensitivity than ionization chambers. The electron density of silicon in
diodes is approximately 18,000 times greater than that of air, meaning that a silicon diode is vastly
more sensitive to radiation dose than an air-cavity ion chamber, even when the diode volume is
significantly lower. Diodes require regular recalibration in order to be used for absolute dosimetry, as
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they acquire cumulative radiation damage over time, reducing their sensitivity by displacing Si
atoms from their lattice positions.
The diode array used in this work was housed within the MapCHECK 2 phantom, model 1177 (Sun
Nuclear Corporation, Melbourne, Florida), which consists of 1527 N-type SunPoint diode detectors
that are uniformly spaced in a 32.0 x 26.0 cm2 2D array, housed in acrylic casing. The shape of the
array can be seen in Figure 1.8. Each detector has an active volume of 0.019 mm3. The diodes are
soldered to metal pads on two circuit boards, which are mounted parallel to one another with an air
gap between. Conductive acrylic plates envelope the diodes, providing shielding from the
radio-frequency fields produced in the waveguide of the linac. This phantom geometry is more
explicitly suited for use with IMRT QA, as one can eliminate any need for angular correction factors
to be applied if one keeps the plane of the array face orthogonal to the source of radiation at all
times. For IMRT QA, this can be performed by either attaching the array to the collimator during
gantry rotation, or by configuring a dummy treatment plan that delivers each field with the gantry
set at zero degrees, while leaving the phantom on the couch.
Jursinic et al. showed that commercially available surface diodes can have up to ± 12% change in
sensitivity as a function of the angle of incident radiation, due to the presence of a copper plane on
the circuit board. Diodes used by SNC for their MapCHECK and ArcCHECK phantoms have a
similar design, with a copper backing that results in a significant angular dependence. By
comparison, prototype diodes with no copper back plane were found to have a ± 3.6% angular
dependence [54]. The introduction of an additional layer of copper above the diode’s active junction
can significantly reduce the angular dependency, but increases perturbation of the radiation field [55].
1.6.2 Phantoms
In the context of radiation therapy, phantoms are structures designed for housing dosimeters at
reproducible locations, for physical analysis of treatment plans. They generally consist of materials
with composition and density close to that of water, in order to approximate the physical and
electron densities of tissues in the patient.
The other phantom used in this thesis for measurement of patient plans was the ArcCHECK
phantom (Sun Nuclear Corporation, Melbourne, FL), seen in Figure 1.9. ArcCHECK consists of an
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Figure 1.8: Surface of MapCHECK, showing positions of diodes in array. Central diode column
is highlighted in yellow. Diodes are housed at a depth of 12 mm below the upper surface of the
phantom.
acrylic cylinder, within which are housed 1386 diode detectors in a spiral pattern. By taking the
beams for the treatment plan and applying them to a computed tomography (CT) scan of
ArcCHECK within the TPS, one can predict the dose you would expect each individual diode to
receive were the ArcCHECK placed in the position of the patient during treatment. Comparing the
expected dose to the actual delivered dose then provides the physicist with the ability to determine
whether the plan is acceptable to deliver.
1.6.3 Gamma analysis
Gamma analysis was introduced as a technique for comparing a reference dose distribution with an
evaluated dose distribution. At its most basic level, it measures two functions: the dose difference at
each point in the distribution, and the distance-to-agreement (DTA), whereby the evaluated dose
distribution is searched to locate the nearest point with the same dose value, and the distance
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Figure 1.9: ArcCHECK phantom, in position on treatment couch. The hole for ion chamber
insertion is at the superior end of the phantom.
between these two points is recorded [56,57]. The comparison is carried out on a point-by-point
basis in a multidimensional spatial frame, in which the calculated and measured dose distributions
are overlaid on one another. Acceptance criteria are measured in a space composed of dose and
spatial coordinates, with the acceptance criteria forming an ellipsoid surface centred on individual
measurement points [57]. If the calculated dose distribution surface intersects with the ellipsoid,
then the calculation passes the gamma criteria for that point. A more complete description of the
technique is outlined in the seminal paper by Low et al. [57].
An example of gamma analysis in a single plane can be seen in Figure 1.10 using the commonly used
gamma criteria of 2%/2 mm. It can be seen that the measured dose is slightly colder than the
calculated dose at the centre of the distribution. At these points, γ > 1, indicating that the gamma
calculation does not meet the acceptance criteria. For this plan, the gamma pass rate, or number of
points meeting the acceptance criteria, was 87.1%.
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Figure 1.10: Example of gamma analysis in one dimension. Set 1 refers to measured point
doses, whereas Set 2 is the calculated reference dose distribution for comparison.
1.7 Receiver Operating Characteristic curves
The Receiver Operator Characteristic (ROC) curve is a tool that can be used to evaluate the
sensitivity (SN) and specificity (SP) of discrete classifier tests with binary outcome trees [58], and in
particular to compare diagnostic tests and test parameters [59]. This makes the ROC curve a useful
tool in radiotherapy for optimization of PSQA processes, which require high SN and SP to be
clinically useful. In other words, it is desirable for QA to accurately identify plans that are being
delivered incorrectly, while also identifying those plans that are ready to be delivered to patients.
An example of an ROC curve can be seen in Figure 1.11. The curve consists of multiple connected
points known as discrete classifiers. The classifier is a diagnostic test which yields two discrete results
- for instance, positive or negative. These results can then be classified as TP, TN, FP, and FN (true
positives, true negatives, false positives, and false negatives), which can be used to determine the SN
and SP of the test. This can be done simply via use of a confusion matrix, as shown in Figure 2.6 in
Section 2.5. Hence each discrete classifier generates a (FP rate, TP rate) pair which corresponds to a
single point in ROC space [60]. By varying the pass threshold of a classifier in a continuous fashion,
one can generate an ROC curve similar to that shown in Figure 1.11, since the variation of the
threshold will vary each of TP, TN, FP and FN. Fawcett [58] and Lasko et al. [60] both provide
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excellent introductions to ROC curve analysis, in general and medical settings, respectively.
Figure 1.11: Example of an ROC curve. The algorithm for the curve connects the points for
classifiers A to I. A test with perfect accuracy would have a curve running vertically from
(0,0) to (0,1) and then horizontally to (1,1), while a test that performs no better than random
guessing would run diagonally from (0,0) to (1,1), as denoted by the blue dashed line.
Several features in Figure 1.11 are worth noting. Point A at (0,0) is a discrete classifier that
represents the strategy of never issuing a positive classification. While this strategy will prevent any
false positive errors from being committed, it also gains no true positives. The opposing strategy
(always issuing a positive classification) is represented by point I, at (1,1). The blue dashed line
represents the strategy of randomly guessing a class. For instance, a classifier at the point (0.7,0.7)
would guess the positive class 70% of the time; this strategy would be expected to guess 70% of
positive instances correctly but would also have a false positive rate of 70%. The hypothetical point
(0,1) would represent the perfect classifier - a strategy that would theoretically produce no false
positive errors and classify all positive instances correctly. Hence it can be seen that classifiers (and
associated ROC curves) appearing closer to the top-left corner of the graph in ROC space are
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preferrable. This would indicate that the classifier is correctly exploiting some information about the
class [58]. Any points or curves below the blue dashed line are performing worse than the strategy of
randomly guessing a class, which could mean that the classifiers have useful information about the
class, but they are applying the information incorrectly [61].
In general, classifiers in the upper right-hand corner of ROC space are considered ’liberal’, in that
they make mostly positive classifications even with weak evidence, creating a high true positive rate
but also generating a high false positive rate. Classifiers in the lower left-hand corner of the ROC
graph are considered ’conservative’, as they only make positive classifications with strong evidence,
meaning they make few false positive errors but their true positive rates are often low [58]. Hence in
Figure 1.11, it would be difficult to choose one classifier as being clearly superior to the rest. One
could argue that D is closest to the northwest corner of the graph, but since this classifier is quite
conservative, it may not be desirable for the particular test being implemented. For instance, if one
wishes to label a higher number of cases as being positive (even at the risk of increasing the false
positive rate), one may wish to use a more liberal classifier in order to increase their true positive
rate. This is a common scenario that is encountered in PSQA, as will be explained later in this thesis.
1.7.1 Indices of accuracy
Visually, ROC curves serve as a useful qualitative analysis of the SN and SP of a diagnostic test.
However, there are several quantifiable ROC curve indices that can be calculated in order to
compare diagnostic tests.
One of the most commonly used ROC indices, and easiest to interpret, is the area under the ROC
curve (denoted as AUC). An ROC curve representing a perfect test has an AUC of 1.0, since the
curve will cover the entire chart, while an ROC curve representing a classifier of random chance
produces an AUC of 0.5. Hence higher AUC values are desirable, while an AUC under 0.5 either
indicates that the test is poorly designed or is interpreting data incorrectly [58]. In the context of
PSQA, the AUC has several interpretations - the average sensitivity of the test for all specificity
values, the average specificity of the test for all sensitivity values, and the probability that the test
will rank a randomly chosen plan that passes relevant tolerances higher than a randomly chosen plan
that exceeds said tolerances [60].
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In order to calculate an AUC curve from test data, one must derive the true ROC curve from a finite
dataset of discrete classifiers. This is analagous to the inference of a continuous statistical
distribution from a finite sample [60]. The simplest method of doing this is known as the empirical
or nonparametric method, in which the ROC curve is approximated by connecting each of the
discrete points (SN,1-SP) linearly. The estimated AUC is then calculated the trapezoidal rule.
While this method has the advantage of having no assumptions about the data, it results in an AUC
that is biased downward when the number of points on the curve are limited [60].
A weakness of the AUC parameter lies in the fact that a high-AUC classifier can theoretically
perform worse in one section of ROC space compared to a low-AUC classifier - i.e. when the
classifier curves intersect and cross at one or more points. For instance, if two classifiers must
produce a specificity above 80% in order to be useful, then the superior classifier should be chosen
based on performance in this useful range. If the classifier curves cross, then the partial area under
the curve (pAUC) may be a more accurate measure of classifier performance [60].
With this deficiency in mind, a useful compliment to the AUC is the Youden index, which provides
more specific information regarding the efficacy of individual classifiers, rather than the test as a
whole. The Youden index can be simply calculated via the following equation:
J = sensitivity + specificity − 1
where J is the Youden index, also known as Youden’s J statistic [62]. The value for the index is
between 0 and 1 inclusive, where 0 indicates a test that is no better than random guessing, and 1
represents a perfect test [62]. In the context of PSQA, the Youden index may be used as an aid for
determining optimal criteria for the detection of treatment delivery errors.
1.7.2 Thesis objectives
This thesis aims to determine whether MapCHECK in MapPHAN is a viable alternative to film for
performing QA on DCAT lung SABR plans. In particular, it aims to assess the efficacy of the
phantom at detecting dosimetric errors in OARs, a topic which is scarcely covered in the literature.
This will be achieved via ROC curve analysis of introduced errors that were delivered to the
phantom, both in silico and directly to the MapPHAN on a linac.
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Chapter 2 presents the materials and methods used in this study. It details the techniques used for
evaluation of errors introduced in silico to lung SABR plans, and the methodology for delivering
these plans on a linac as a comparison to the in silico analysis. It also includes a description of the
methods used for commissioning the MapPHAN prior to measurement.
Chapter 3 contains the results generated during this thesis. It links the in silico analysis to the
phantom measurements via ROC curve analysis, and includes an overview of the results obtained
during commissioning of the phantom, with a particular emphasis on the angular dependency
corrections performed. The optimal gamma criteria for use in PSQA with this phantom are
determined, using the results from the ROC curve analysis.
Chapter 4 is a discussion of the results found in Chapter 3, in which the effect of the angular
dependency corrections on the phantom measurements is discussed, and compared with the
literature. The statistical accuracy of the ROC curve analysis is scrutinized, along with its potential
clinical relevance. Potential areas of future work are also indicated.
Chapter 2
Materials & Methods
This study was comprised of two broad experimental sections. In the first experiment, errors were
introduced to lung SABR plans in silico on a treatment planning system, in order to calculate the
effect of these errors on the dose distributions of each plan. In the second experiment, these plans
(with and without errors) were physically delivered to a phantom, and a robustness analysis was
performed on the QA results achieved with the phantom. The sensitivity and specificity of
MapCHECK in MapPHAN to detect clinically significant errors were determined by analysing the
combined results of both experiments.
The broad focus of this thesis was on the sensitivity and specificity of the MapPHAN phantom to
introduced errors, with a specific focus on OAR dosimetry, since the QA of PTV doses has already
been extensively covered in the literature [63–68].
2.1 In silico analysis of introduced errors
Twenty-three patients treated for lung cancer using DCAT lung SABR at Auckland Hospital were
randomly selected for inclusion in this experiment. Of these, fourteen patients received 48 Gy to the
PTV in 4 fractions, and nine had 60 Gy delivered to the PTV in 8 fractions. All plans were
originally delivered using 6 MV flattened X-ray beams on a Varian Clinac iX linac (Varian Medical
Systems Inc., CA, U.S.A.). Each plan had been previously optimised in Pinnacle v9.8 or v9.10
(Koninklijke Philips N.V., Amsterdam, Netherlands). Target volumes and OARs were delineated by
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the treatment planners and radiation oncologists at Auckland Hospital. Patients were scanned in CT
with hands raised above their heads, immobilized in the supine position. The Varian Real-Time
Position Management Gating System (Varian Medical Systems Inc., CA, U.S.A.) was used to
generate an ITV, via reconstruction of eight breathing phases captured in CT. An isometric margin
of 5 mm was then added to the ITV volume to generate the PTV contour. The OARs delineated for
these plans included the chest wall, brachial plexus, great vessels, heart, oesophagus, proximal
bronchus, ribs, skin, trachea, external, and lungs. Additionally, for some 60 Gy plans, the spinal cord
PRV and a volume containing the entire lung minus ITV were contoured. Not all OARs were
contoured in each plan, and for certain OARs (such as the spine), only the clinically relevant portion
of the OAR was contoured, since any volumes outside of the treatment region would have no
significant effect on dose statistics. The planning isocentre was located as close as possible to the
PTV centre, within the maximum allowed lateral couch position of 3.5 cm (in order to avoid
collisions between the gantry and the couch during gantry rotation). The minimum arc length for
each plan was 180o, with typical arc length being 200-220o and each plan being split into either two
or three arcs, each with 5o spacing between control points. Beam entry through the contra-lateral
lung, spine and heart was avoided where possible.
The plans for these patients were anonymised in Pinnacle, then transferred across to Raystation v5.0
(Raysearch Laboratories, Stockholm, Sweden). This TPS provides efficient tools for the editing of
plan parameters and subsequent calculation and comparison of these plans. Prior to transferring
these plans to Raystation, the control point spacing for these plans was reduced from 5o to 4o per
control point, in order to facilitate the transfer of these plans between the two TPS’s. This had the
additional benefit of slightly improving the accuracy of the treatment planning calculation, although
calculation time increased by 25% as a result of the increase in control point number.
2.1.1 Raystation simulations
Two types of error were introduced to the treatment plans - isocentre shifts and systematic MLC
shifts, known as class open errors. Raystation was used to introduce errors in the position of the
plan isocentre using incremental errors of 0.2 mm, up to a maximum error of 1 mm, which is the
tolerance for disparity between mechanical and radiation isocentre at Auckland Hospital. The
isocentre was shifted both ways along all three cardinal axes - inferior-superior, right-left, and
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anterior-posterior. This could be considered analogous to shifting the CT dataset in the opposite
direction to the isocentre shift. In order to introduce MLC errors, Python 2.7 [69] was used to
generate a script that could edit parameters in DICOM (Digital Imaging and Communications in
Medicine) files, which are a standard for containing data structures that are commonly utilised in
medicine [70]. This script (which can be found, along with the requisite DICOM tags, in Section 1 of
the Appendix) was used to introduce errors in the planned MLC positions for each patient, with
incremental class open errors of 0.2 mm being added to widen the MLC aperture for all leaves on
both MLC banks. For some of the plans, errors were introduced up to a level of 2 mm in order to
investigate the expected trends. However, for the majority of plans, the errors were introduced up to
a level of 1 mm, as this is the tolerance for MLC position accuracy at Auckland Hospital. As closing
of the aperture would have produced a decrease in the calculated dose to all tissues, which is not
detrimental to OARs, this type of error was not introduced to the plans.
An example of a class open MLC error is shown in Figure 2.1. It can be seen that any tissue directly
beneath the blue sections (close to the PTV boundary) would be most significantly affected by the
introduction of these errors, as the removal of shielding allows these sections to be directly
irradiated. Tissue adjacent to these sections will also receive an increase in dose due to increased
scatter from the blue tissue regions, but the dose contribution from scatter is far smaller than that
from direct irradiation.
Figure 2.1: Beam’s eye view of example PTV (red) beneath MLC leaves for one control point
in a conformal arc plan (not to scale). Introduction of MLC class open errors is shown in blue.
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Dose distributions for plans, both with and without introduced errors, were calculated in Raystation
5.0, based on the parameters set in the DICOM files. An IGRT couch model was generated in
Raystation for each patient, to simulate the position of the couch during actual treatment. A dose
grid voxel size of 0.2 x 0.2 x 0.2 cm3 was used to calculate each plan. DVH metrics were recorded for
both the original and edited plans, as shown in Table 2.1. These metrics were chosen based on the
constraints used by the planners to optimise the plans, which in turn were based on international
recommendations and clinical results, such as the RTOG 0813 lung SABR trial [71, 72].
Table 2.1: Recorded DVH metrics for both edited and original plans.
PTV dose
48 Gy 60 Gy
OAR Planning tolerance
Brachial plexus Dmax ≤ 36 Gy
Chestwall V30 Gy ≤ 70 cc V30 Gy ≤ 70 cc
External Dmax ≤ 78 Gy
Great vessels Dmax ≤ 45 Gy Dmax ≤ 54 Gy
Heart Dmax ≤ 30 Gy Dmax ≤ 44 Gy
Oesophagus Dmax ≤ 27 Gy Dmax ≤ 40 Gy
Proximal bronchus Dmax ≤ 30 Gy Dmax ≤ 44 Gy
Spinal cord (PRV) Dmax ≤ 28 Gy
Trachea Dmax ≤ 30 Gy Dmax ≤ 44 Gy
Whole lung - ITV V20 Gy ≤ 15%
Whole lung V5 Gy ≤ 60%
Ribs Dmax ≤ 40 Gy
Skin Dmax ≤ 36 Gy
The maximum point dose for each contoured organ within the plan was calculated in Raystation and
recorded. These values were plotted as a function of both the incremental MLC and isocentre errors.
The gradients of these plots were then used to determine the significance of the introduced errors.
2.2 Commissioning of MapPHAN
The phantom used in this thesis was the MapCHECK 2, Model 1177. This was mounted between
two slabs of solid water which comprised part of an old MapPHAN accessory, previously designed for
use with the MapCHECK 1 phantom (Model 1175). To fit the MapPHAN accessory to the
MapCHECK phantom, two solid water inserts with dimensions of 11 mm x 29 mm x 300 mm were
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fitted between the two MapPHAN slabs. This was done so the inserts abutted the left and right
sides of the MapCHECK phantom, as seen in Figure 2.2.
Figure 2.2: Image of the MapPHAN setup used in this thesis, without MapCHECK inserted.
Only the top and bottom layers of solid water were from original MapPHAN phantom. The
entire phantom can be disassembled by removal of the screws in the cradle.
Sun Nuclear provides the MapPHAN as a solution for the QA of rotational arc therapy treatments.
However, there are caveats to this statement. The documentation accompanying the accessory [73]
states that the phantom should be placed in a coronal orientation when the majority of dose being
delivered is incident from either anterior or posterior beams at G0 and G180. Likewise, if the
majority of incident radiation is coming from a lateral direction (around G90/G270), then the
phantom should be oriented in the sagittal position. The manual states that this practice ’minimizes
angular dependence and maximises the dose map measurement area’. The manual goes on to state
that ’Compared results in Relative Dose mode may display a low pass rate’ if the dose is normalised
to the point of maximum dose, and this point varies significantly from other points. The probability
of this occurring ’increases when the MapCHECK/MapPHAN assembly is irradiated from an angle
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other than zero degrees’. These statements throw into question the validity of using this device for
any sort of rotational delivery, unless additional steps are taken to minimise the angular dependence
of the device. This has been performed before using various methods [74–76], but due to the unique
geometry of the in-house MapPHAN setup used in this experiment, it was decided to analyse the
angular dependencies of the phantom in full detail.
The use of 5 g cm-2 of buildup material is recommended by Sun Nuclear for two main reasons: to
achieve higher precision in high dose gradient regions, and to minimize scatter radiation to the
instrument electronics [73]. The phantom used in this thesis only provides 2 g cm-2 of
water-equivalent buildup along its lateral sides, with 5 g cm-2 provided on the top and bottom
surfaces. However, this was deemed appropriate for use in 6 MV beams, as it provides greater depth
than the 1.5 g cm-2 required to avoid measuring in the buildup region of the 6 MV PDD (not
including the additional plastic on the sides of MapCHECK itself). While scatter radiation is, in
theory, an increased factor in the measurement of lateral beams for this phantom, the proportion of
control points with beams passing directly through this section of the phantom is relatively low for
full conformal arc treatments. Additionally, the shorter range of scattered radiation makes it more
likely to be absorbed by diodes on the periphery of MapCHECK’s array. During the course of this
thesis, it was found that the dosimetrically valid portion of the phantom was comprised of the diodes
within 4 cm laterally of the central phantom diode column, based on the angular dependency
measurements taken in Section 3.2. Hence it was assumed that scatter radiation had a minimal
effect on measurement, as the majority of scattered radiation would be absorbed prior to reaching
the diodes at this depth in the phantom. This is discussed further in Section 3.2.
The MapCHECK phantom itself had previously been commissioned for use within the department,
using documents such as the AAPM TG40 report [77] as guidelines for IMRT commissioning
standards, among others. This meant that parameters such as dose rate dependency, scatter
response, dose reproducibility and dose linearity had already been investigated and controlled for.
However, the phantom had only been previously commissioned for receiving beams orthogonal to the
array plane, where the phantom was always placed in the same orientation relative to the gantry.
This limits the device to performing what is essentially a fluence-based measurement for IMRT plans.
MapPHAN, on the other hand, is designed to allow the MapCHECK phantom to be irradiated from
all gantry angles. This allows measurement of plans delivered using arc therapy techniques.
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In order to complete the commissioning process, four key operations needed to be performed:
• Quantify the angular dependency of the diodes within the phantom;
• Model the phantom (MapCHECK housed within MapPHAN) with appropriate physical and
electron density overrides in Raystation, in order to correctly simulate the dose delivered to
the phantom for each plan;
• Perform an absolute dose calibration on the central diodes of the phantom;
• Perform end-to-end testing of the phantom with both generic conformal arc beams and patient
plans, in order to test the accuracy of the dose calibration and density overrides.
The methodology of how the above were performed is outlined in the following subsections.
2.2.1 Angular dependency of diodes and determination of density
overrides
The phantom was scanned using a Philips Somatom Sensation CT scanner, in both coronal and
sagittal orientations. The scans were then imported into Raystation, where streak artefacts were
noticed in the plane of the detectors, as can be seen in Figure 2.3. In addition to the streaks in the
detector plane, a secondary streak pattern was observed radiating outwards from the diode plane,
whereby the CT reconstruction algorithm calculated the density of materials closer to the array as
being denser than those at a greater distance. This was confirmed by obtaining readings of the
Hounsfield units measured at different points in the solid water, as viewed in Raystation. These
artefacts have been reported previously by multiple authors [74–76]. Keeling et al. performed a
similar analysis of the percent dose difference between measured and planned doses with no density
overrides applied, reporting up to a 38% discrepancy between measured and calculated doses for 6
MV X-ray beams with 5 x 5 cm2 fields [74]. The dependency was slightly lower for a 10 x 10 cm2
field, and significantly lower for similar measurements performed with 10 MV, presumably due in
part to the fact that the attenuation coefficients of the diode materials decrease as the photon energy
increases.
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Figure 2.3: Transverse slices taken from CT scans of MapPHAN in sagittal and coronal orienta-
tions, with mass density overrides applied. A Varian couch model has been included. Note the
streak artefacts in the plane of the diode array. All material contours were generated with an
electron density equal to that of water, as per Sun Nuclear recommendations for the standard
MapPHAN.
The angular dependency is worst at gantry angles of 90o and 270o, where the beam axis is parallel to
the detector array. This increases the attenuation of the beam and accentuates the inherent angular
dependencies of the diodes themselves [74]. The increased attenuation of the beam in the plane of
the diodes can be observed in Figure 2.3, where dark streak artefacts are seen in the plane of the
diode array, which contains circuit boards with high atomic number materials that significantly
attenuate low-energy X-rays produced by CT scanners. This effect has also been observed by
Jursinic et al., who used a MV CT scanner with higher energy X-rays that aren’t preferentially
attenuated to the extent that kV X-rays are. Use of the MV scanner reduced the streak artefacts to
the point that the density of the phantom could be derived directly from the CT scan [75]. As no
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MV CT scanner was available at Auckland Hospital, another method was necessary to determine the
densities of the materials housed within the phantom.
Lacking the ability to perform MV CT imaging, it was decided that the best alternative would be to
apply density overrides to all sections of the phantom (including materials of known density) in
order to reduce the dependency to acceptable tolerances. Using the scanned phantom model in the
coronal orientation, density overrides for the phantom’s contours were determined by using the
angular dependency measurements with the phantom in the coronal orientation. These overrides
were then applied without modification to the phantom model in the sagittal orientation.
Jursinic et al. [75] claim to have reduced the angular dependency of the MapCHECK phantom from
± 20% to within ± 2%. Based on their MV CT images, they were able to deduce that the mean
density of their MapCHECK phantom was 1.21 g cm-3, while the mean density of the solid water in
MapPHAN was 1.05 g cm-3. Using these applied densities, they measured the resultant angular
dependency of the phantom using 25 x 25 cm2, 6 MV X-ray beams delivered to the central diode of
MapCHECK, which was aligned with linac isocentre. These beams were delivered at 15 degree
increments through all gantry angles. Both measured and calculated doses were recorded for the
central diode, and the ratio taken to determine the accuracy of the calculated doses. Due to the lack
of a suitable MV CT scanner for accurate measurement of the array densities, it was decided that
optimising the phantom densities in an inverse manner would be the most practical solution. By
performing angular dependency measurements and comparing the dosimetric results to those
calculated in Raystation, the appropriate mass and electron densities of the phantom materials could
be optimized in Raystation.
The overrides were optimised in an iterative fashion. With the phantom placed at isocentre, 10 x 10
cm2 fields of 100 MU, 6 MV X-ray beams were delivered to the phantom at static gantry angles
through the full range of gantry angles (shown in Figure 2.4) at increments of 10o for each beam.
(The choice of 10 x 10 cm2 represents a standard field size that provides close to full scatter
conditions for the central diode column, while also being close to the relative size of the fields used
for SABR.) Raystation was used to calculate the expected dose to the five central diodes of the
phantom for each delivered beam. The ratio of the measured and expected doses for the mean dose
recorded by the 5 most central diodes was then calculated for each beam, after normalisation to the
G0 measurement. From these ratios, a chart of the angular dependence based on the relative dose
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obtained at each gantry angle was generated. As an additional analysis tool, the dose distributions
for both the measured and computed beams were compared using SNC Patient software (Sun
Nuclear Corp., Melbourne, Florida). By changing the material overrides on the simulated phantom
in an iterative fashion, the agreement between measured and calculated doses at the centre of the
diode array was optimized. By taking the mean dose from the five central diodes, rather than the
dose from the central diode only, the statistical uncertainty in these measurements was reduced.
Since the maximum lateral separation between the central five diodes is 1 cm, it can be assumed
that the dose falloff over this region from lateral beams is approximately linear. Hence by taking an
average of the doses measured in this 1 x 1 cm2 region, one can obtain an accurate assessment of the
dose at the central diode, with better statistics than would have been obtained from a single point
dose measurement.
2.2.2 Conformal arc measurements
Following the application of density overrides, conformal arc beams were delivered to MapPHAN to
determine the accuracy of the overrides. Three 360o arc beams of 600 MU each were delivered to the
centre of the coronal phantom, with 10 x 2 cm2, 10 x 5 cm2, and 10 x 10 cm2 field sizes respectively.
The same arcs were simulated in Raystation. The doses received by the MapCHECK array were
imported into SNC patient software, which produced a visual readout of the point doses on the
array. These were then compared to their respective Raystation-calculated dose distributions.
Additionally, film measurements were taken to determine the actual field size as set by the jaws
during delivery of these arcs, in order to ensure that the output of the linac matched that being
simulated in Raystation. Film was placed at the level of isocentre, with 5 cm of solid water buildup
placed on top of the film, and another block of solid water placed underneath the film. 6 MV X-ray
beams were delivered at G0. The field sizes were then determined as the average distance between
the 50% isodose lines in the beam profiles produced by SNC, in accordance with how the jaws were
originally calibrated. All field sizes were within ± 2% of the expected results.
All conformal arc plans had a collimator offset of either 10o or 350o, which eliminated the MLC
tongue-and-groove effect. This occurs when diode detectors aligned in the plane of the MLC’s
inter-leaf gaps receive extra dose as the gantry rotates in the plane of these gaps, due to the reduced
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Figure 2.4: Raystation contours of MapPHAN in coronal orientation, with gantry angle co-
ordinates overlaid.
shielding provided by these gaps. This effect has been observed to decrease the gamma pass rate for
plans without collimator rotation that were checked with MapCHECK 2, if not accounted for [78].
2.3 Patient specific quality assurance measurements
This section outlines the methodology behind all physical measurements performed on the linac.
This includes the measurement of both the original and edited patient plans on MapCHECK in
MapPHAN, along with the validation measurements performed for these plans, performed with film
and ionization chamber measurements in the ArcCHECK phantom.
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2.3.1 MapPHAN measurements
Once commissioning of the MapPHAN was completed, the template for the phantom with
appropriate density overrides was saved in Raystation for use in PSQA. The plan parameters for the
original patient plans were applied to this template to simulate the expected dose distributions on
this phantom, which were then saved as DICOM RTPlan and RTDose files. The treatment plans
(both original and with MLC and isocentre errors applied) were then physically delivered to the
phantom using the same Varian Clinac iX linac. From the 23 patients selected for this study, 10 were
selected for linac measurements. The original DICOM plan files, along with the plans with MLC
edits included, were all transferred electronically to the linac in order to be delivered physically.
Isocentre shift plans were delivered by physically shifting the patient couch to simulate
misalignments between the machine isocentre and planning isocentre, while MLC errors were
introduced by the modified DICOM files for each patient plan, which were exported directly from
Raystation. Of these 10 patients, one was excluded from measurement due to the necessity of
introducing couch shifts to correctly align the dose distribution with the phantom isocentre. This
prevented the introduction of an unnecessary confounding factor. The parameters for these plans
were used to calculate dose distributions on the simulated MapPHAN phantom in Raystation, using
both the original plans, and plans with MLC and isocentre shifts included. The RTPlan and RTDose
DICOM files (containing the plan parameters and plan dose data, respectively) for these virtual
plans were exported from Raystation and imported into SNC Patient. This software allows the
virtual plans to be compared to the actual dose delivered to the phantom using gamma analysis.
The physical phantom was aligned with the mechanical isocentre of the linac using the in-room
lasers, as shown in Figure 2.5. Couch shifts were simulated on the MapCHECK phantom model in
Raystation for each plan, in order to align the region of maximum dose with the central diode of the
MapCHECK phantom. These couch shifts were then replicated when performing physical
measurements on the linac. This was done for two reasons. Firstly, the region close to the point of
maximum dose is in a low dose gradient region. This allows the physicist to take point dose
measurements with greater accuracy at the centre of the dose distribution; any sub-millimetre
misalignments will shift the point of measurement within this homogeneous dose region, with
negligible effect on the measurement. Secondly, the angular dependency measurements revealed that
measurements taken within 5 cm of the central diode were most accurate; this is outlined in detail in
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Section 3.2.
Figure 2.5: Setup used for MapCHECK inserted into MapPHAN, placed on the linac couch.
The linac head can be seen at the top right hand corner. The central diode in the phantom
was aligned with the machine isocentre by aligning the isocentric lasers with lines painted on
the phantom.
MapCHECK has a dose calibration tool which allows the phantom to correct for daily fluctuations in
linac output. The phantom is set up under conditions with a known central axis dose, which is
calculated in Raystation prior to delivery. This can theoretically be performed for any level of
buildup, as long as it is compensated for in Raystation. Prior to all measurements, 100 MU of 6 MV
X-rays were delivered to the phantom with the central diode positioned at isocentre, in order to
calibrate the device. Initially, the device was calibrated using a single solid water slab which
provided 3 cm of water-equivalent buildup material. Following analysis of the plans, the device was
calibrated within the MapPHAN accessory (which also consists of solid water), which provided 5 cm
of water-equivalent buildup. The choice of calibration technique had a significant effect on the
outcome of the experiment, and this is discussed in the Results section.
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2.3.2 ArcCHECK measurements
In order to validate the quality of the plans being delivered to MapCHECK, a near-identical process
was performed to generate simulated dose distributions on the ArcCHECK phantom created by
SunNuclear. ArcCHECK has a film insert which can be used purely for film measurements without
measuring the dose in the diodes. It also has an insert with a hole for insertion of a CC04 ionization
chamber at the centre of the phantom. This setup can then be used to perform point dose
measurements for each QA plan. For this project, the diode array in ArcCHECK was not used for
measurements, with only point dose measurements being taken.
Point dose measurements
Ion chamber measurements were performed for the nine original plans that were delivered to
MapCHECK, using a 0.04 cc Scanditronix/Wellhofer CC04 ionization chamber (IBA Dosimetry,
Schwarzenbruck, Germany) coupled with a UNIDOS E Electrometer (PTW, Freiburg, Germany).
For these measurements, a PVC insert was placed inside the ArcCHECK phantom, and the chamber
placed inside the centre of the insert. As with the MapPHAN measurements, the plan was calculated
on the CT dataset containing the simulated version of the phantom in Raystation, with couch shifts
applied to ensure that the maximum dose region of the dose distribution was centred on the ion
chamber position.
Film measurements
As a further validation of the plans being delivered to MapCHECK, film QA was performed on three
of the nine original plans, using a film insert which was placed in the centre of the ArcCHECK
phantom. As with the ion chamber measurements, the simulated dose distribution was aligned with
the central part of the film, using couch shifts which were then replicated on the linac.
40 Chapter 2. Materials & Methods
2.4 Analysis of MapPHAN measurements
Analysis of the measured plans involved comparing the measured dose distribution in each respective
phantom to the simulated dose distribution generated by Raystation, using SNC Patient software.
This takes point doses in the measured dose distribution (in the case of MapCHECK, doses from
each diode; in the case of film, a grid is applied with dose measured at regular spatial intervals) and
compares them to the continuous dose distribution surface plot generated by Raystation. Gamma
analysis was then performed to obtain a quantitative analysis of the affinity between the measured
and simulated dose distributions.
Six gamma analysis settings were used: 1%/1 mm, 2%/1 mm, 2%/2 mm, 3%/2 mm, 3%/3 mm, and
5%/1 mm. These gamma criteria are commonly used clinically, and are pertinent to SABR due to
their low distance specifications, all being less than or equal to 2 mm, which is representative of the
stringent setup margins required for accurate SABR delivery. As per ADHB protocol, shifts were
automatically applied in SNC Patient to align the measured and calculated dose distributions in an
optimal fashion. This is done to account for setup error on the part of the physicist. Following
application of shifts, the dose recorded in the central diode of the phantom was tabulated for each
plan, as well as the disparity between the recorded and calculated central diode dose.
For all measurements, a gamma threshold of 10% was set, meaning that any points receiving dose
below 10% of the maximum point dose were not included in the final gamma calculation. This is
normal clinical practice, in order to exclude points in low dose regions where the dosimetric
uncertainty is highest. Since none of the DVH metrics for OARs (as shown in Table 2.1) were
affected by volumes receiving doses below 10% of the PTV dose - 48 Gy or 60 Gy - this is acceptable
practice.
A 0.8% measurement uncertainty was applied to all absolute dose comparisons, which consisted of
the following errors defined by SNC:
• Measurement electronics error: 0.08%
• Array calibration uncertainty: 0.5%
• SSD uncertainty (2 mm at 100 cm SSD, combining QA and calibration setup errors): 0.4%
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• LINAC output fluctuation: 0.15%
• Diode temperature dependence (based on room fluctuation and array gradients of 1oC: 0.5%
These errors were then combined in quadrature according to the GUM (Guide to the Expression of
Uncertainty in Measurement) [79] method of analysing errors to obtain a standard uncertainty of
0.8%, with coverage factor of 1 [80]. This was added to the percent tolerance in the gamma analysis.
For instance, the 1%/1 mm criteria is actually calculated by using cutoff criteria of 1.8% dosimetric
difference and 1 mm shifts. No angular dependency correction was included in these errors, despite
the fact that SNC designed MapCHECK for use in the MapPHAN phantom, and includes this
uncertainty (0.5%) in measurements made for ArcCHECK.
2.5 ROC curve analysis
In order to determine the sensitivity and specificity of the MapCHECK phantom to the introduced
plan errors, ROC curves were generated using the ’ROCR’ package created by Sing et al. [81] in the
statistical programme R [82]. The classifiers used in this thesis were based on the confusion matrix
shown in Figure 2.6. Several common metrics can be calculated from this matrix, including:
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From these metrics, the ROC curve itself is built, with TPR (or sensitivity) on the ordinate and
FPR (or 1 - specificity) on the abscissa.
Figure 2.6: Confusion matrix (also known as a contingency table) used for generation of ROC
curves specific to OARs in this thesis.
In the context of Figure 2.6, only plans that had OAR tolerances exceeded in Raystation as a direct
result of introducing an error had a hypothesised class of positive. That is, if a fully optimised plan
with no introduced errors already included an OAR that was receiving in excess of a tolerance dose,
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then this plan should still have passed QA (with hypothesised class being negative), assuming it was
being delivered as intended. The assumption was made that any Type A errors generated during the
delivery of certain plans were negligible compared to the errors being deliberately introduced.
Following generation of the curves, the AUC and Youden index were used to determine the optimum
gamma criteria to be used for PSQA.
Chapter 3
Results
3.1 In silico analysis of introduced errors
3.1.1 Dosimetric comparison between edited and original plans
As a preliminary analysis, a dosimetric comparison was performed between the original plans and
the plans with the most substantial errors introduced, using the dose difference tool in Raystation’s
plan evaluation module. This was performed as a qualitative analysis to reveal the regions with the
greatest dosimetric fluctuations relative to the position of the PTV, upon introduction of errors to
the plans. The comparisons were performed for both the conformal arc plans and VMAT plans.
Figures 3.1 and 3.2 show the dosimetric effect produced by 1 mm MLC opening and 1 mm isocentre
shifts for one patient plan, which was indicative of the MLC results in general. The results, when
combined with the analysis data in Figures 3.3 and 3.4, provide some insight into the general regions
that are most likely to be influenced by introduced errors. For MLC deviations, the effect is most
pronounced in the region directly beneath the MLC positional shift, as traced from the virtual
source of the beam to the point in the patient. This is as expected, since a variation in MLC
position is effectively an addition (leaf closing) or subtraction (leaf opening) of beam shielding along
the ray line.
As can be seen in Figure 3.2, shifting the isocentre anterior resulted in a dosimetric shift that was
44
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Figure 3.1: Transverse images of original plan, plan with 1 mm MLC errors introduced, and
dosimetric comparison between two plans, respectively, for patient 3. The key for the dosimetric
comparison shows the percent dosimetric difference between the two plans.
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Figure 3.2: Transverse images of original plan, plan with 1 mm isocentre shift introduced, and
dosimetric comparison between two plans, respectively, for patient 3. The key for the dosimetric
comparison shows the percent dosimetric difference between the two plans.
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approximately symmetrical on either side of the PTV. That is, an increase in dose on one side was
matched in turn by an approximately equivalent decrease in dose on the other side of the target
volume. This approximate symmetry was observed in most plans, although occasionally an
asymmetry was observed for certain plans. This is likely due to the position of the PTV relative to
the boundary of high and low density tissue, where the lung and ribcage interface, thus changing
radiation scatter conditions for these regions.
3.1.2 DVH measurements
Maximum point dose measurements
Point dose measurements were performed for all patients. Figure 3.3 contains point dose
measurements for patient 3, with and without introduced MLC class shift errors. Linear trend lines
with associated uncertainties were drawn through the data, using least-squares regression in Excel.
The standard error in these measurements was estimated at ± 8%; the reasoning behind this is
discussed in Section 4.1.
Figures 3.5 to 3.8 contain the gradients produced from the trend lines in Figures 3.3 and 3.4. In
these plots, the initial maximum point dose was measured from the original plan calculated in
Raystation, while the gradient was measured from the linear trendlines plotted as a function of the
introduced errors. As an example, in Figure 3.5, the point at (19.95, 1.45) refers to a single patient’s
maximum point dose calculated in the proximal bronchus. The introduction of MLC errors produced
an increase in this maximum point dose, at a rate of 1.45 ± 0.12 Gy per mm (2 SD) of class shift
error introduced to the plan. Hence if the plan was delivered with 1 mm MLC class shift error, one
would expect this patient’s ribs to receive a maximum point dose of 21.40 ± 0.12 Gy.
In theory, this is not a significant issue for this particular plan. The dashed lines in Figure 3.5
indicate the planning constraints for each OAR. For the proximal bronchus, the constraint is 30.00
Gy, meaning that the proximal bronchus for this patient received a tolerable dose. Assuming that the
MLC position accuracy is kept within 1 mm (a parameter that is checked during routine linac QA),
this OAR dose is only likely to exceed the constraint if a gross treatment error were to occur. Hence
the introduction of MLC errors should not be of concern to the clinician for this particular OAR.
48 Chapter 3. Results
Figure 3.3: Maximum point dose measurements obtained for patient 3, for plans with and
without introduced MLC class shift errors. For this patient, errors were introduced up to 2
mm, in order to ascertain the extent to which the trends obtained were linear. In the majority
of patients, the gradients were calculated only up to 1 mm of introduced MLC error.
However, there are plans for which the introduced MLC error could have significant detriment to
OARs. Take the point in Figure 3.5 at (38.56, 4.04), which refers to a single patient’s maximum
point dose to the ribs. The constraint for this OAR lies at 40.00 Gy; the plan is designed to achieve
a maximum point dose to the ribs that is below this point. So the original plan has passed the
constraint value for the ribs. However, it can be seen that the introduction of a class shift MLC error
would eventually lead to this constraint being exceeded. Using the information provided, the
expected MLC error required for failure can be calculated as:
Error = c− xy
where c is the value of the constraint, in Gy, and (x, y) denotes the location of a point on Figure 3.5
(x being the initial maximum point dose, in Gy, and y being the gradient calculated from Figure X,
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Figure 3.4: Maximum point dose measurements obtained for patient 3, for plans with and
without introduced isocentre shift errors. The mean absolute point dose change was calculated
based on the results from shifts in all six anatomical axes.
in Gy/mm). In the case shown above:
Error =
40.00 Gy − (38.56± 3.08) Gy
4.04 Gy/mm
= 0.36± 0.03 mm
Hence one would only need to introduce an MLC class shift error of approximately 0.36 mm to
exceed the constraint. In reality, it is unlikely that such an error would occur. MLC leaf errors tend
to be random in nature, although systematic errors are often seen in individual leaves. The caveat of
all this is that for certain plans, the introduction of errors will (in theory) have a minimal effect on
the clinical effectiveness of the treatment plan. This is the case for plans where the DVH result for
any specified metric isn’t close to the tolerance for that metric. However, it is generally the case that
there will be at least one metric that is close to tolerance, when compared to the standard
uncertainty in the metric.
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Figure 3.5: Maximum point dose gradients generated from introduction of MLC errors to
plans with a PTV dose of 48 Gy. Dashed lines indicate thresholds at which associated OAR
constraints should fail, if potential MLC-induced dosimetric error is taken into account. Error
bars quoted to within ± 2 SD.
In almost all volumes calculated for each patients, gradients calculated for the isocentre shift trends
were slightly affected by a systematic decrease in calculated dose, which appeared at the
introduction of a 0.6 mm isocentre shift. This can be clearly seen in Figure 3.4, and can potentially
be attributed to the dose grid, although the exact cause is uncertain. In general, the decrease in
gradient that occurred as a result of including these points was less than 2% for all patients, which is
negligible when considering the uncertainties involved in these measurements. Furthermore, the
error appeared to be systematic for almost all volumes measured. Therefore, this phenomenon is
unlikely to have had a significant effect on the trends observed in Figures 3.7 and 3.8.
Volumetric measurements
Two OARs in Table 2.1 had DVH constraints that analysed the percentage volume of the OAR
receiving in excess of a threshold dose. For instance, the constraint for the whole lung in plans with
48 Gy prescribed to the PTV was V5 Gy ≤ 60%. The change in these values as a function of the
introduced MLC and isocentre shift errors was also plotted, in a manner identical to that used for
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Figure 3.6: Maximum point dose gradients generated from introduction of MLC errors to
plans with a PTV dose of 60 Gy. Dashed lines indicate thresholds at which associated OAR
constraints should fail, if potential MLC-induced dosimetric error is taken into account. Error
bars quoted to within ± 2 SD.
the maximum point doses. The gradients of the resulting graphs were calculated, and the results
plotted. These results can be found in the Appendix (Figures 1 to 8). In general, the density of data
acquired was too low to produce any quantifiable claims about trends. However, there were points
that fell close to the boundary, in a similar manner to the maximum point dose measured in the ribs
for one patient, referenced in Section 3.1.2.
3.2 Commissioning of MapPHAN
The majority of the commissioning process was concerned with the application of appropriate
density overrides for the phantom, in order to correct for the angular dependencies of the diodes
within the phantom. The results from this process are outlined in detail in the subsections below.
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Figure 3.7: Maximum point dose gradients generated from introduction of isocentre errors to
plans with a PTV dose of 48 Gy. Dashed lines indicate thresholds at which associated OAR
constraints should fail, if potential MLC-induced dosimetric error is taken into account. Error
bars quoted to within ± 2 SD.
3.2.1 Angular dependence of diodes and determination of density
overrides
The process of determining appropriate density overrides for the phantom proved to be complex, as
in addition to the inherent angular dependency of the diodes, several other confounding factors had
to be accounted for. Sun Nuclear recommends that a uniform density override of 1.05 g cm-3 be used
for the entirety of the phantom, including the diode array. However, the results indicated that this
did not provide accurate agreement between measured and calculated doses delivered to the
phantom.
Figure 3.9 shows the mean angular dependence of the central five diodes, with a uniform density
override of 1.05 g cm-3 applied to the entire phantom in Raystation. The central five diodes are
arranged in a 1 cm x 1 cm ’X’ shape at the centre of the phantom. The maximum discrepancy
between measured and calculated results was observed at gantry angles G90 and G270 (11.9% and
13.3% respectively). This is similar to results obtained in the literature; for instance, Jursinic et al.
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Figure 3.8: Maximum point dose gradients generated from introduction of isocentre errors to
plans with a PTV dose of 60 Gy. Dashed lines indicate thresholds at which associated OAR
constraints should fail, if potential MLC-induced dosimetric error is taken into account. Error
bars quoted to within ± 2 SD.
found that application of a uniform density override generated a measurement over-response of 24%
at G90 and G270, and an underresponse of 8% at G180, where the beam is delivered through the
back end of the phantom [75]. Other centres have discovered similar results, but have overcome this
by simply avoiding the delivery of beams at G90 and G270 [74]. The alternative suggested by Sun
Nuclear is to rotate the phantom by 90o into the sagittal orientation, for beams that are delivered
from these directions. Since this technique does not work for most rotational beam deliveries, which
typically subtend a wide arc of gantry angles, it was decided to reduce the angular uncertainty to
within ± 2% if possible via the application of density overrides in the TPS.
Optimization of density overrides
Figure 3.10 shows the final results for the angular dependence obtained using the optimized density
overrides found in Figure 2.3. The data shown here represents the measurements for diodes within ±
40 mm laterally of the central MapCHECK diode. Results for all diodes can be found in Figure 9 in
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Figure 3.9: Mean ratio of calculated/measured dose for central five diodes of MapCHECK in
MapPHAN, with uniform density override of 1.05 g cm-3 applied to entire phantom. Error bars
represent uncertainty of± 2.06%, which combines in quadrature the uncertainty of central beam
axis dosimetry in Raystation with the relative dose measurement uncertainty of MapCHECK.
All errors quoted to within ± 2 SD.
the Appendix. The inclusion of measurements from diodes at a distance greater than 40 mm from
the central diode significantly increases the variation in dosimetric discrepancy between measured
and calculated doses for individual diodes. The maximum angular dependency of the central diodes
was found to be equal to ± 4.15% for the coronal orientation, and ± 3.20% for the sagittal
orientation. The assumption was made that there was no significant aliasing in these measurements,
although it is possible that the angular dependency is higher than the figures stated here.
Sun Nuclear recommends that the electron density applied to the phantom should be equal to that
of water. During the process of modifying the density overrides, it was found that changing the
electron density had a negligible effect on dosimetry when compared to changing the physical
density. This was also the case for the diode array itself, which contains materials with markedly
differing electron density to that of water. However, reference to Figure 1.3 indicates that for 6 MV
X-ray beams, pair production becomes more predominant for higher atomic number materials, such
as those found in the array. This has the potential to significantly affect the Raystation-calculated
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dose in these regions, especially for lateral beams passing parallel to the array. Despite this, it was
decided to maintain a uniform electron density throughout the entire phantom, since the problem of
optimizing the angular dependency was already a complex multi-variate problem. The accuracy of
the results obtained was sufficient to back up this methodology.
The MapCHECK phantom itself consists of multiple layers of plastic, which were not identical in
density and had to have density overrides applied to reflect this. Additionally, there was found to be
a small cylindrical hole in the posterior plastic backing of the phantom, directly below the central
diode. Hence adding this feature to the model significantly improved dosimetric results for the
central diodes, which were directly adjacent to this hole.
Since lung SABR plans have such a high dose falloff, the majority of diodes outside of this central
diode region will register doses lower than 10% of Dmax, meaning they are not considered for the
gamma calculation. For certain plans, a very low number of diodes outside of the central diode
region exceeded the gamma threshold while simultaneously exceeding the 10% threshold required for
inclusion in the measurement. An example of these points can be seen in Figure 3.13. The gamma
comparison shows some points well outside of the central PTV dose region which are nonetheless
exceeding the gamma threshold comparison. These points are closest to the left edge of the phantom
(which is set up in the coronal orientation). For this plan, the range of gantry angles utilised was
from G181 clockwise through to G20, meaning that the majority of radiation was delivered passing
through the left side of the phantom. The resultant elevation in dose on this side of the diode array
allows these points to exceed the 10% threshold required for the points to be included in the gamma
analysis.
These diodes are theoretically beyond the buildup region for 6 MV X-rays in terms of
water-equivalent thickness of material, so the reason for this discrepancy is not immediately clear.
The effect could potentially be explained by the fact that closer to the edge of the phantom, the
density override for the diode array has a greater effect on the Raystation calculation. This
conclusion can be reached from a geometric basis. The arc subtended by the beam as it passes
through the phantom to reach the diodes at this point will pass laterally through the phantom for a
greater proportion of the arc than it would for diodes at the centre of the phantom. It is possible
that this phenomenon had a biasing effect on the overall gamma results, since the homogeneity and
baseline of the low dose region would have varied between plans as a function of the gantry angles
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used for beam delivery. As a result, this effect was more pronounced for certain plans where a higher
proportion of dose was delivered laterally through the array. Overall, the gamma pass rate did not
decrease too significantly for these plans - the case shown in Figure 3.13 was one of the worst
examples, and still produced clinically acceptable gamma pass rates. However, it is certainly
something to keep in mind when performing QA, as this effect could generate a number of false
positives if it leads to QA failures.
Comparison between coronal and sagittal orientations
The mean dose discrepancy for the central diodes is shown in the trend lines of Figure 3.10. Overall,
the measured dose was slightly higher than the calculated dose for both the coronal and sagittal
orientations. As the density overrides were chosen based on the angular dependency results in the
coronal orientation, the mean dosimetric discrepancy between measured and calculated doses for
these angular dependency beams was slightly lower than for the beams delivered to the phantom in
the sagittal orientation, which had identical density overrides applied. While the discrepancy was
still within the recommended tolerance of ± 2%, it is significant enough to be taken into account
when performing PSQA.
The mean discrepancy for the central diodes across all gantry angles is 0.11% greater for the sagittal
orientation than for the coronal orientation (0.39% and 0.28% respectively). While this is a small
discrepancy overall, the number of diodes from which these statistics were measured is great enough
to suggest that this difference is significant, and attributable to something other than output
fluctuations in the linac. While the phantom is rotated, in theory this should have no effect on the
dose it measures, as the linac is designed to produce consistent radiation output independent of
gantry angle. Ignoring phantom rotation, the other major change in experimental setup is the
position of the couch relative to the central diodes. With the phantom positioned at isocentre, the
couch is closer to the average diode position when the phantom is in the coronal orientation. It can
be inferred that dosimetric uncertainties propagated into the angular dependency measurements that
are inherent to the couch model will have a greater effect on results obtained with the phantom in
the coronal orientation. This is because more beams passed through the couch to reach the phantom
when it was in the coronal orientation, as a consequence of the couch being moved closer to isocentre
while positioning the phantom. While this is a possible cause of the 0.11% discrepancy, further
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Figure 3.10: Ratio of calculated/measured dose for diodes within ± 40 mm of central diode
along central transverse axis, for angular dependency measurements on MapCHECK in coronal
(top) and sagittal (bottom) orientations. Trend line represents mean discrepancy for each
gantry angle. The mean discrepancy for the central diodes across all gantry angles was 0.28%
for the coronal orientation, and 0.39% for the sagittal orientation. Error bars represent 1 SD
from the mean discrepancy for all central diodes.
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measurements could be performed to determine the true extent of the couch model uncertainty. The
couch model was initially commissioned in such a way that 1% dosimetric accuracy was attainable in
the TPS, so this error is certainly comparable to any uncertainty in the couch model’s dosimetric
accuracy. Unfortunately, the commissioning data for the couch model could not be obtained at the
time of writing.
Standard deviation of dosimetric discrepancy as function of gantry angle
SNC Patient software provides a histogram of measured versus calculated values when gamma
analysis is performed. From this, the mean disparity for diodes along the central transverse axis of






where Di = (measured dose - calculated dose)/(calculated dose) for histogram bin i, and fi is the
number of measurements for this bin. The standard deviation of the disparities for all central axis
diodes was calculated via the following equation:
σ =
√∑
i(fi × (Di −Dmean)2)∑
i(fi)− 1
(3.2)
The final density chosen for the array itself was 0.80 g cm-3, going counter to the idea that the array
consists of high-Z materials, which typically have a greater density than that of water (1 g cm-3).
However, it can be seen upon close inspection of the CT scan that the array consists of both
circuitry and a large number of air pockets, which significantly reduced the mean density of the
array as a whole.
In order to compensate for the inherent angular dependency of the diodes, the density override for
the array was altered so that the Raystation-calculated dose distributions for beams passing parallel
to the plane of the array were optimally aligned with the measured doses of the most central diodes
to within the desired tolerance of ± 2%. Figure 3.11 shows that applying this density override
provided a central region of approximately 80 mm width that was acceptable for use in PSQA of arc
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treatments, based on the 2% tolerance. The extent of this agreement can be used to determine the
restrictions that should be placed on the device when using it for PSQA - i.e. limitations on the
PTV size that can be accurately measured with gamma analysis on the device.
Figure 3.11: Screenshots of agreement between the measured dose for MapCHECK 2 in coronal
orientation (Set 1, with individual points representing the dose measured at each diode at
distance X mm from the central diode in the transverse plane), versus Raystation calculated
dose (Set 2, black line). The upper figure shows the agreement when a uniform density override
of 1.05 g cm-3 was applied to the entire phantom. The lower figure shows the agreement
following the correction of the array override to 0.80 g cm-3. Yellow points indicate agreement
within ± 2% between the measured and calculated dose, with red and blue points representing
diode measurements that lay outside of this tolerance.
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Figure 3.12 shows the SD calculated for the diodes along the central axis of the phantom, for both
coronal and sagittal orientations. Compared to the calculation of mean discrepancy, the SD provides
additional information about the degree to which outliers are present in the dataset. Hence a large
standard deviation with a low mean discrepancy likely indicates that there is an offset in the
discrepancy that is balanced out on either side of the array, as can be seen in Figure 3.11.
It should be noted that a larger discrepancy is expected when the peripheral diodes are included, as
the 10 x 10 cm2 fields used in these measurements did not cover the entire array. Hence some of the
diodes will only be receiving scattered and leakage radiation, primarily from the phantom and linac
head. Dosimetric accuracy in these out-of-field regions is expected to have greater uncertainty.
However, beams delivered at gantry angles within 10o of the array plane (G90/G270 for coronal, and
G0/G180 for sagittal orientation) included all central axis diodes in the central beam region. (Even
beams delivered at gantry angles 20o from the array plane, such as G70 for the coronal phantom,
included over 90% of the central axis diodes in the central beam region.) Despite this, the SD for all
diodes is highest in these regions where the beam is delivered parallel (or close to parallel) to the
array plane. This is further evidence of the inherent angular dependencies of the diodes themselves.
An additional complication is the increase in SD observable for beams delivered through the back
end of the phantom. For the coronal orientation, this is seen between approximately G110 and G250,
whereas for the sagittal orientation, this is observed between approximately G200 and G340. Sun
Nuclear have stated that the diodes in MapCHECK were primarily designed for radiation delivered
through the front end of the phantom, implying that the dosimetric uncertainty for beams delivered
through the back end of the phantom is higher. There is also a greater water-equivalent thickness of
material for the beam to penetrate to reach the diodes through the back end of the phantom, and
different material overrides were applied to the top and bottom layers of the MapCHECK phantom.
Both of these factors may be contributing to the increase in SD.
It was concluded that utilising MapCHECK in MapPHAN for the QA of conformal arc SABR plans
is clinically acceptable, as long as appropriate restrictions are set in place for use of the device. The
choice to limit the device’s bounds to ± 4 cm from the central diode column is conservative, based
on the misaligned dose distributions seen in Figure 3.11. However, this sets approximate boundaries
for consistent 2% dosimetric agreement with Raystation, entirely independent of the angle of
radiation delivery.
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Figure 3.12: Standard deviation as a function of gantry angle for MapPHAN in both coronal
and sagittal orientations.
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3.3 Patient specific quality assurance measurements
3.3.1 Conformal arc commissioning measurements
In order to confirm the validity of the density overrides in the previous section, three conformal arc
beams were delivered to MapCHECK in MapPHAN, using a 10 x 2 cm2 field, a 10 x 5 cm2 field, and
a 10 x 10 cm2 field. The measured results were compared to their respective calculated dose
distributions via gamma analysis, with 1%/1 mm criteria. The resultant gamma pass rates were
95.2%, 95.3%, and 83.9% respectively, for the field sizes listed. The measured and calculated dose at
the point of the central diode was also recorded for all three measurements, with the disparity being
equal to -2.22%, -1.59%, and -1.29% respectively. This indicated that the calculated dose was
systematically higher than the measured dose, with the disparity increasing for smaller field sizes. It
was decided that these results were acceptable for commissioning purposes, given that the tolerance
for 2%/2 mm gamma criteria at ADHB is 85%, and the gamma criteria being used here were more
strict than this. Additionally, the tolerance for absolute dose disparity is ± 3%, and all central diode
disparities were less than this value. This test was not an entirely fair representation of the plans
that were actually delivered, since it utilised the linac jaws to set field sizes rather than the MLC,
which has a greater transmission factor for radiation. However, the difference between transmission
factors was negligible compared to the 3% absolute dose tolerance required. Hence it was decided to
continue with measurement of actual patient plans.
3.3.2 PSQA measurements
Nine patients with plans that had introduced errors were delivered to the phantom - in total, 198
plans were generated for the final analysis. All plans were delivered on the same Varian Clinac iX
System linear accelerator (Varian Medical Systems, Palo Alto, California). SNC Patient software
was used in conjunction with MapCHECK for these measurements. Two measurements were taken
for each plan, with the phantom offset by 5 mm superior via couch shift for the second measurement.
These two measurements were then merged in SNC Patient software, thus doubling the effective
dosimeter resolution of the phantom.
It was assumed that the linac used for measurements was able to deliver both the modified and
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error-free plans with equal bias. For example, any MLC delivery error was assumed to be consistent
between these two groups, regardless of the degree to which test errors were introduced. This
assumption applied to all variables on the linac (e.g. collimator angle, gantry angle, MU output,
etc.). In reality, an accumulation of these random and systematic errors will have reduced the
accuracy of gamma analysis for all plans.
Figure 3.13: Example of gamma analysis for one patient, using 1%/1mm gamma analysis crite-
ria. Top left: measured doses as delivered to MapCHECK in MapPHAN. Top right: Raystation
calculated doses. Bottom left: agreement between measured and calculated doses for individual
diodes on MapCHECK. Red points indicate that the dose received by MapCHECK was greater
than the Raystation calculated dose at that point (outside of the 1%/1mm threshold), while
blue points indicate that the measured dose was lower than the calculated dose. Bottom right:
dose profile through MapCHECK at the level of the green line.
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3.3.3 ArcCHECK measurements
Film measurements
As a ’gold standard’ for reference, film measurements were taken to confirm the validity of the plans
being delivered, with film inserted into ArcCHECK in both coronal and sagittal orientations. The
high resolution capabilities of film were used to confirm that MapCHECK in MapPHAN would be
sufficient for analysis of the high dose gradient regions present in the SABR plans being delivered.
Table 3.1 contains the results for relative film measurements performed on both plans calculated in
Raystation and Pinnacle. Three of these measurements fell just outside of the 2%/1 mm threshold of
85% passing points, with the worst of these being at 84.1%. This indicated that there was generally
good agreement between the treatment planning systems and the delivered doses. In addition, three
of the plans had a disparity of greater than 5% between the Pinnacle-calculated dose distribution
and the Raystation-calculated distribution, for their respective gamma passing rates. For two of
these plans, using Raystation to calculate the dose actually increased the gamma pass rate,
indicating that it would be acceptable to use Raystation for calculation of conformal arc plans in
place of Pinnacle, where the plans were originally calculated.
Table 3.1: Gamma analysis results comparing Raystation- and Pinnacle-calculated doses to
measured doses for film measurements taken in ArcCHECK phantom, measured in both coronal
and sagittal orientations. Three original patient plans were measured. The thresholds for
passing the analysis were 85% for 2%/1 mm and 90% for 3%/1 mm.
1 2 3
Coronal Sagittal Coronal Sagittal Coronal Sagittal
Raystation
2%/1 mm 88.0 95.6 84.1 90.1 89.3 85.5
3%/1 mm 94.4 99.7 94.2 98.7 98.9 98.9
Pinnacle 2%/1 mm 87.3 84.2 95.6 84.3 85.2 86.3
3%/1 mm 93.7 95.9 97.8 94.0 97.0 98.5
Point dose measurements
As a final, gold-standard validation of the accuracy of delivery of the original plans, point dose
measurements taken on the nine original plans were analysed. These plans were delivered to the
ArcCHECK phantom with acrylic insert, using a 0.04 cm3 CC04 ionization chamber placed at its
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centre to measure the dose. The couch was shifted for each plan to ensure that the chamber was
positioned in a high-dose, shallow dose-gradient region, which simultaneously increased statistical
counting accuracy and decreased geometrical uncertainty. The recorded dose for each plan was
normalised to the dose received by the chamber after delivery of 200 MU of 6 MV X-rays through a
10 x 10 cm2 field at G0. This normalised dose was then compared to the normalised doses calculated
in Raystation for the same phantom. The expected agreement between the measured and calculated
doses was ± 3%, as per recommendations laid out by IAEA Human Health Series No. 31, ESTRO
Booklet No. 9 and similar publications [83,84].
The agreement between measured and calculated dose was well within the requisite tolerance for all
9 plans, as shown in Table 3.2. This, coupled with the agreement between the measured and
calculated central diode readings on MapCHECK in MapPHAN, along with the gamma pass results,
provided sufficient evidence that the phantom was ready for clinical use.
Table 3.2: Point dose measurements recorded with CC04 ionization chamber placed inside
ArcCHECK phantom. All plans fell within the specified tolerance of ± 3%.
Patient number Calculated dose/Gy Normalised measured dose/Gy Agreement/%
1 7.06 7.04 0.3
2 11.99 11.90 0.7
3 12.56 12.53 0.2
5 14.00 14.06 0.4
6 6.51 6.44 1.1
7 6.53 6.52 0.1
8 11.07 11.06 0.0
9 12.79 12.80 0.1
10 11.04 11.10 0.5
3.4 Analysis of MapPHAN measurements
Table 3.3 contains the mean gamma pass rates for plans with and without introduced errors, for all
gamma thresholds used. The mean disparity between the measured and calculated dose at the
central diode is also included.
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There are several key points that can be derived from this table. Firstly, in general, the introduction
of isocentre shifts has little effect on the mean gamma pass rate for each set of criteria, when
compared to the introduction of MLC errors. The result of this is seen in Section 3.5, where the
sensitivity and specificity of MapCHECK to introduced isocentre errors is shown to be worse than
random guessing for several gamma criteria. The effect of including automatic shifts in SNC Patient
software is a general increase in the pass rate for all gamma criteria. This has repercussions which
can be observed in the ROC curve results for these criteria (refer to Section 3.5).
In terms of gamma pass rate, the effect of doubling the effective resolution of MapCHECK by
merging two measurements has no discernible effect on the final results. All mean gamma pass rates
have overlapping error brackets of 1 SD for each combination of gamma criteria and error, suggesting
that there is no significant increase in accuracy when detection resolution is increased. Based on
these results, increasing the resolution is only necessary when one is looking for points measured in
the high dose gradient region, as these points can be vital for determining why the plan failed QA.
For non-stereotactic plans, increasing the resolution of MapCHECK will probably not provide any
additional valuable information to the physicist, since the sample size provided by the standard
MapCHECK diode resolution is probably sufficient for these plans.
All mean central diode disparities listed were below ± 1.5% from the expected result. The maximum
disparity recorded for any individual central diode reading was -2.83%. Point dose measurements are
expected to be within ± 3.0% of the expected measurement [83,84], hence the results obtained here
indicated acceptable agreement for commissioning standards that pertain to absolute dosimetry.
3.5 ROC curve analysis
Figures 3.14 and 3.15 show the ROC curves generated using the ROCR package, via comparison
between the gamma analysis results and the actual DVH metric standards.
Based on Figure 3.14, it appears that MapCHECK in MapPHAN is proficient at detecting
introduced MLC errors, with sensitivity and specifity comparable to that seen in the literature. The
shapes of the curves in both coronal and sagittal orientations are relatively similar, for their
respective gamma criteria. For instance, the results for 3%/3mm show a slight dip below the line of
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Figure 3.14: ROC curves generated from merged MapPHAN results with multiple gamma
analysis criteria, for plans with introduced MLC shift errors delivered to MapPHAN in both
coronal (top) and sagittal (bottom) orientations.
y = x for both orientations, although the magnitude of this dip is greater for the coronal orientation
results. Similar trends can be seen for the other criteria. Hence, assuming that variations in these
trends are statistical in nature, it can be concluded that neither phantom orientation produces
superior sensitivity or specificity for the detection of introduced MLC errors. Since MLC shifts are
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performed in an axis orthogonal to both of these phantom orientations, this result makes sense; in
any case, the rotational nature of delivery ensures that the dose variation is spread out relatively
isotropically around all edges of the target volume, as seen in Figure 3.1.
The results in Figure 3.15, on the other hand, suggest that the phantom exhibits poor sensitivity
and specificity to introduced isocentre shift errors. The ROC curves tend to fall below the line of
y = x, suggesting that the phantom may be performing worse than random guessing for detection of
these errors. These were unexpected results, but multiple secondary checks of individual classifier
points were performed to validate the charts. Assuming that the tests are not applying information
incorrectly, it can be tentatively concluded that these results are statistical aberrations. This is
plausible, considering the low data density for the isocentre shift results. Due to the increased risk of
linac collisions when performing QA, some patient plans were removed from the analysis. More plans
were removed from QA for the sagittal case, since this phantom orientation increased the risk of
collisions significantly. Hence any quantitative conclusions derived from these results carry less
weight than those derived from the MLC shift results.
Additionally, the AUC for each curve was calculated in the ROCR package. These results are shown
in Table 3.4.
Table 3.4: AUC for ROC curves for both isocentre and MLC shift errors, using all 6 gamma
criteria. Both merged and unmerged results are shown, with the phantom in both coronal and
sagittal orientations. The maximum discrepancy between any pair of merged and unmerged
results in this table is 0.16, while the mean discrepancy between pairs in this table is 0.07 with
a SD of 0.04.
Error type Phantom
orientation
1%/1mm 2%/1mm 2%/2mm 3%/2mm 3%/3mm 5%/1mm
Merged
Isocentre Coronal 0.15 0.18 0.15 0.22 0.18 0.42
Isocentre Sagittal 0.52 0.67 0.43 0.48 0.32 0.64
MLC Coronal 0.64 0.62 0.50 0.46 0.45 0.73
MLC Sagittal 0.58 0.62 0.61 0.70 0.62 0.78
Unmerged
Isocentre Coronal 0.13 0.18 0.19 0.29 0.20 0.46
Isocentre Sagittal 0.66 0.59 0.28 0.32 0.44 0.74
MLC Coronal 0.54 0.50 0.43 0.38 0.38 0.61
MLC Sagittal 0.64 0.67 0.60 0.71 0.61 0.88
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Figure 3.15: ROC curves generated from merged MapPHAN results with multiple gamma
analysis criteria, for plans with introduced isocentre shift errors delivered to MapPHAN in
both coronal (top) and sagittal (bottom) orientations.
3.5.1 Comparison of merged and unmerged results
The results shown in Figures 3.14 and 3.15 were generated using the merged measurements, in which
the dose was measured twice - the second time with the phantom shifted 5 mm superior to the
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original phantom position. ROC curves were also generated for the unmerged results, where
measurements were only taken with the phantom in the original position on the couch. These can be
seen in Figures 10 and 11 in the Appendix, while the AUC of these curves is included in Table 3.4.
The low mean discrepancy between the pairs of merged and unmerged AUC results is reflected in the
low mean discrepancy observed between the pairs of merged and unmerged gamma analysis results.
3.5.2 Application of automatic software corrections for isocentre
shift results
Initially, SNC shifts were calculated for all plans, as per ADHB protocol. However, the ROC curves
generated for the isocentre shift errors suggested that inclusion of these automated corrections was
reducing both the sensitivity and specificity of the phantom to these geometrical errors. In order to
determine if this was the case, the computed and measured plans were compared again in SNC
Patient, this time without the application of shifts. The results of this analysis can be observed in
Figure 3.16. Once again, the AUC for each curve was calculated, as shown in Table 3.4.
There is a significant improvement for the results obtained with the phantom in the coronal
orientation, as seen in the mean increase in AUC of 0.19 for measurements taken without automatic
shift corrections. However, in the sagittal orientation, the sensitivity and specificity actually
decreases overall, with a mean decrease in AUC of 0.16 for measurements taken without automatic
shift corrections. It is likely that this is due to the low data density in the regions of the curve that
contribute most significantly to the AUC. In general, the 1 mm isocentre shifts did not generate
significant dosimetric fluctuations, meaning that the majority of datapoints contributed to the point
(1,1) in ROC space (representing perfect sensitivity but zero specificity). Data that contributes to
this point in ROC space does not affect the calculation of AUC in any way. Considering that the
AUC is only an indication of the sensitivity and specificity of gamma criteria as a whole, the specific
thresholds which would be applied clinically are not being specifically analysed here. Assuming the
data for the phantom in the coronal orientation is statistically significant, it should be concluded
that including shifts in SNC Patient significantly reduces the sensitivity and specificity of the
phantom to introduced geometrical errors.
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1%/1mm 2%/1mm 2%/2mm 3%/2mm 3%/3mm 5%/1mm
No
Coronal 0.42 0.44 0.35 0.41 0.29 0.57
Sagittal 0.27 0.37 0.25 0.40 0.44 0.34
Yes Coronal 0.15 0.18 0.15 0.22 0.18 0.42
Sagittal 0.52 0.67 0.43 0.48 0.32 0.64
Correlation between gamma pass rates and AUC
Figure 3.17 shows the mean gamma pass rates for each type of introduced error, for all gamma
thresholds used during this experiment. The error bars in this chart can be interpreted as the degree
to which the introduced error changed the gamma pass rate. For instance, the variance in the 1%/1
mm results due to introduced MLC errors shows that the introduction of these errors generated a
large change in the gamma pass rate; this is confirmed in Table 3.3. The figures also confirm that
the introduction of automatic shifts in SNC significantly increases the mean gamma pass rate for
isocentre shift errors.
An attempt to determine any potential correlation between mean gamma pass rate with the AUC for
each level of introduced error was made. The results for this analysis were not statistically relevant
due to the low number of datapoints available, but still provided some insight into the nature of
potential relationships between the pass rate and AUC. This is discussed further in Section 4.5.1.
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Figure 3.16: ROC curves generated from merged MapPHAN results, with no SNC shifts applied,
for plans with introduced isocentre shift errors delivered to MapPHAN in both coronal (top)
and sagittal (bottom) orientations.
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Figure 3.17: Mean gamma pass rates for all introduced errors (MLC and isocentre shift errors),
with phantom in coronal and sagittal orientations.
Chapter 4
Discussion
Several studies analysing PTV doses and associated QA have been previously carried out [63–68].
This thesis focusses instead on the QA of OAR doses, a topic which is scarcely covered in the
literature. As far as the author knows, the closest study of this type was performed by Kim et al.,
who used ROC curves to analyse the sensitivity of the gamma index to introduced errors, but did
not focus on OAR doses, and only studied MLC shift errors [65]. This thesis reinforces some of the
conclusions of this paper, while introducing several unique concepts.
4.1 In silico analysis of introduced errors
The choice of machine errors to introduce into the sensitivity analysis was mainly determined by the
predicted influence these errors would have on the treatment plan and resultant dose distribution. A
literature review suggested that introducing errors in MLC position and performing isocentre shifts
would have the most significant influence on plan outcomes [63–68,78,85,86]. In addition, the
magnitude of the errors was limited to the machine QA tolerances applied at Auckland Hospital,
which made the results both efficient in their determination and practical for application at this
centre. For the MLC errors, the magnitude of the resultant dosimetric changes was significant within
these tolerances, perhaps suggesting that a review of these tolerances could be appropriate. However,
studies focussing on PTV dose have indicated that gamma analysis is not sensitive to isocentre shift
errors less than 2 mm [63]. If anything, this study on OAR doses does not disprove this outcome.
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It is worth noting that in reality, every treatment plan has some level of error in every continuously
definable parameter. Therefore, statistically, some plans will be afflicted by a combination of errors
that results in significant dosimetric disparities, while the combination of errors for other plans will
result in smaller disparities. This is why QA is an absolute necessity, in order to identify the plans
that are most afflicted by combined errors. MLC position and isocentre shift errors comprise only
two of these parameters, but represent a large proportion of the entire scope of potentially
deliverable treatment errors. Hence as an analytical tool, the introduction of these types of error can
provide a good indication of the robustness of the quality assurance process, especially when the
errors are pushed to the extent of their tolerances.
MLC leaf position errors have been studied on more complex IMRT plans, but to the author’s
knowledge, this is the first study that looks at conformal arc plans for lung SABR specifically, with a
focus on OAR DVH metrics, rather than on the PTV. The lack of OAR analysis in the literature is
an indication of the priority placed on PTV coverage during QA. Granted, the PTV always takes
highest priority in a radiotherapy plan. However, the priority placed on particular OAR dose
constraints is such that they will shape the treatment plan to a significant degree. It seems logical
that PSQA processes should place a similar (if not identical) priority level on the QA of OAR doses.
Ideally the physicist is also performing a visual inspection of the shape of the dose distribution,
although it can be all too easy to accept a plan that passes all gamma analysis criteria by
themselves. Certain QA techniques provide this level of analysis, showing hot and cold spots in the
plan on the original CT dataset, and allowing the physicist to perform a more thorough analysis of
doses to different volumes of tissue. SNC Patient software does not achieve this level of detail;
ideally it should be used in conjunction with another QA technique in order to achieve this.
It should be noted that doctors will regularly place priority on PTV coverage at the expense of
delivering excessive dose to certain OARs. For instance, it is common clinical practice to permit
excessive dose to be delivered to the ribs and chest wall during lung SABR, significantly increasing
the risk of rib fractures. This is done to prevent excessive constraints from being placed on the
treatment plan, which then allows the planner to improve PTV coverage and potentially reduce dose
to more critical OARs such as the heart and spine. Hence while it should be concerning that these
OARS are receiving excessive dose, there is certainly justification for these doses in many cases.
In retrospect, the choice of conformal arcs for measurement was useful for determining the utility of
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the phantom for rotational deliveries. The simplicity of conformal arc deliveries allowed the
detection of certain errors with greater confidence as to their origin, which would have been more
difficult with the smaller MLC field sizes and intensity modulation of VMAT. An example of such an
error was covered in Section 3.2.1. The detection of the offset between calculated and measured dose
at the proximal end of the phantom (relative to the mean positional origin of radiation delivery)
could clearly be attributed to the phantom structure, as it was appreciated that the dose
distribution was weighted towards the end of the phantom closest to the mean origin of radiation
delivery. The addition of intensity modulation would likely have shifted the weighting of radiation
delivery, making it more difficult to ascertain the source of error.
Estimation of standard dosimetric error
Mzenda et al. performed a comprehensive analysis of the dosimetric equivalence of Pinnacle and
Raystation calculations, as part of the commissioning process for Raystation at Auckland Radiation
Oncology, in a study that was performed with help from members at Auckland Hospital [87]. They
found that open field calculations performed with Raystation agreed with measured results to within
2% for central axis points, within 10% for measurements taken in penumbral regions, and within 4%
for off-axis measurements, quoted to within ± 2 SD. Any point of maximum dose in an OAR
adjacent to the PTV will, at various stages of the treatment, find itself in all three of the beam
regions listed above. Hence the dosimetric uncertainty at this point should be calculated as an
appropriated ratio of the general uncertainties in these regions. Several approximations in the beam
model, and the potential disparity between the accuracy of the beam model at ADHB compared to
that used in Mzenda’s paper, will modify the uncertainties listed above. Therefore it is appropriate
to estimate a conservative standard uncertainty for all results obtained in the following charts.
Hence an 8% standard dosimetric uncertainty was considered appropriate as an estimated
uncertainty in all gradients plotted, quoted to within ± 2 SD. This also assumes a higher uncertainty
in calculating dose in low density lung tissue, due to poor modelling of electron transport using the
collapsed cone convolution algorithm in Raystation [87].
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4.1.1 DVH measurements
The trends obtained in Figures 3.5 through 3.8 were not unexpected. The initial maximum point
dose received by an OAR is, to a certain degree, representative of the proximity of the OAR to the
target volume. This becomes apparent when one looks at Figures 3.1 and 3.2. The most significant
dosimetric increases are observed around the periphery of the PTV, meaning that OARs with tissue
in these regions were most significantly affected by introduced errors.
The choice of DVH metrics for measurement were based on a template for treatment plans at
Auckland Hospital, as this allowed the direct analysis of the QA processes at this centre. By
comparing the change in maximum point dose to the initial maximum point dose received by an
OAR, it was possible to eliminate any uncertainties surrounding geometrical metrics. Initially,
measuring the change in maximum point dose as a function of distance between the PTV and the
specified OAR was considered, but this would have been problematic, since the choice of points used
to measure distance was critical. As this was an OAR based study, points had to be chosen that best
reflected the dose being received by individual OARs. The centroid point of the contoured organ
could have been used, but in many cases this would have been an unfair descriptor of the organ’s
position, due to the variable nature of organ shapes. As such, the centroid position is not a fair
reflection of the dose being received at all points in the organ, most notably since its location is
determined by the planner’s contouring of the organ.
Alternatively, the dose received by the point of the organ closest to the PTV could have been chosen,
but this also was problematic, as the point of location of the PTV itself is often offset from the
location of maximum dose inside the PTV, especially when the PTV is non-spherical in shape. Even
if the point of maximum dose was used as a centre to establish the distance of OARs from the PTV,
the shape of the dose distribution itself would have been a factor introducing variation in the trend,
since the dose gradient is typically sharper in the crossplane direction for conformal arc treatments.
Hence the change in dose was measured as a function of the maximum point dose received by the
organ, which provided a semi-reliable indication of the effect of introduced errors.
However, using this metric brings its own series of uncertainties, the first being the gradient of the
trend itself. As mentioned previously, the introduction of a 0.6 mm MLC error generates an
unexpected dip in the calculated maximum point doses for almost all OARs. Since the source of this
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error is probably associated with the dose grid, it is difficult to eliminate entirely, although it would
be unfair to exclude it from the final results. Secondly, and more importantly, the change in
maximum point dose remains a function of the spatial geometry of the organ relative to itself and to
the PTV. The maximum point dose received by an organ must be a function of the organ’s position
in the dose distribution, but the point of maximum dose may change as errors are introduced into
the treatment plan. This is obviously the case for isocentre shifts, where the shift in dose is in the
direction of the introduced isocentre error. If the phantom geometry is ignored entirely, then the
expected change in dose as a result of shifting the isocentre can be approximated as the differential
of the dose at that point, as a function of the shift. Critically, this means that high dose gradient
regions have the greatest uncertainty when comparing measured and calculated dose distributions,
using gamma analysis or similar. Hence the dose to OARs located in these regions should be more
carefully managed, especially if they are close to recommended threshold doses.
A similar trend is observed in MLC results, although a mathematical basis for the trend cannot be
formulated as simply as for isocentre shifts. The most important similarity between the two trends is
the increase in uncertainty for regions with high dose gradients. In the case of MLC shifts, these
regions lie approximately underneath the edge of the MLC leaves (using a beam’s eye view, as in
Figure 2.1). Hence it would not be accurate to utilise the differentiated dose distribution to analyse
the expected change in dose upon the introduction of an MLC shift error. However, this is an
appropriate technique for determining where the greatest uncertainties in the dose distribution are
located, since as with isocentre shifts, the greatest change will be in the high dose gradient regions.
In order to develop an accurate model of the uncertainty in MLC errors, one would likely need to
perform a meta-analysis of MLC errors in multiple linacs at different clinical centres. This would be
an extremely time-intensive project that would probably not be worth the quantification it provides,
as developments in MLC technology are continually reducing the magnitude of MLC errors.
Interpretation of maximum point dose
The results observed in this thesis highlight how impractical certain metrics can be for planning
purposes. One of the main disadvantages of the DVH is the lack of spatial information that it
provides, in that it does not let the user know where the dose is located. The use of maximum point
dose seems like a particularly arbitrary threshold for measurement, as it provides no spatial
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information about the OAR in question. The main utility of this metric is that it can be used for
protection of serial organs, as the theoretical consequence of exceeding the tolerance dose at one
point in the organ is failure of the organ as a whole. A prime example of this is the spinal column,
which is comprised of millions of neuronal tracts, some of which extend from the brain stem all the
way to the sacrum. Any damage inflicted to these tracts at any point in the cord will result in failure
of the tract as a whole. However, when a maximum point dose exceeds tolerance in a plan, one
should not simply accept this result at face value without considering the uncertainties involved.
Where is the OAR in relation to the PTV? At what location in the OAR is the point of failure?
What is the dose gradient at this point of failure? How far does the high dose region extend into the
OAR? To what extent can the OAR be considered ’serial’ as opposed to ’parallel’, where failure at
one point in the organ does not necessarily constitute failure of the organ as a whole? While the last
question is more medically oriented, the prior questions all require an understanding of the
dosimetric uncertainties involved in the planning process. This all goes to highlight the importance
of not using the DVH as a standalone tool for plan assessment.
Additionally, in several cases, the CTV may be directly adjacent to OARs which then fall in the
bounds of the PTV itself, following expansion of the CTV margins. In these cases, the OAR’s
maximum point dose tolerance will almost certainly be exceeded, making the metric virtually useless
in providing information to the clinician. In these cases, it is vital that a metric is used that
determines dose to the OAR outside of the PTV. One way of doing this is to contour the OAR in
such a way as to exclude any section of the OAR that falls in the PTV. Even in these cases, however,
the maximum point dose will certainly fall on the PTV-OAR boundary, which again renders the
metric somewhat useless as a means of providing information about the OAR to the clinician. This
highlights the fact that the isodose curves on the plan itself should be checked thoroughly, in
addition to the use of relevant DVH metrics. The clinician should also have sufficient knowledge of
the uncertainties involved in these plans, so that they can make a judgement call on dose metrics
that have only just fallen within acceptable tolerances.
The complexity of the human body is such that most radiotherapy plans will fail at least one
threshold for planning tolerance. Hence the planning process always involves some form of cost
optimization process, whereby multiple sub-optimal solutions must be compared and contrasted in
order to generate what the planner believes to be the most suitable plan. Inverse planning invokes a
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multicriteria cost optimization technique known as Pareto optimization, whereby a human operator
sets the boundary constraints on a computational optimizer, which determines the Pareto optimal
point on the boundary of the objective space that the operator has set. If the objective functions are
optimised correctly, then this point will allow the planner to achieve the highest possible plan quality
for those limits, within the bounds of reasonable time constraints [42]. It can be safely assumed that
almost all complex plans will push (and sometimes exceed) their specified OAR tolerances in order
to maximise PTV coverage. It is then left to the clinician to determine which tolerances are
acceptable to push. This is where a complete understanding of the uncertainties involved in these
metrics is invaluable.
Dose grid resolution
One parameter that may have some effect on the maximum point dose metric is dose grid resolution.
For any single OAR, Raystation will collate a matrix of dose voxels within the dose grid, and
calculate the average dose in each voxel. Since the maximum point dose necessarily increases as the
size of each voxel decreases, it is possible that the resolution will have an effect on this metric. Park
et al. examined the optimal dose grid size to use for practical dose calculations using DCAT in lung
SABR. When compared to a 2 mm dose grid size, they found that using a 4 mm dose grid size
increased the dose variation by up to 3-4% (approximately 50 cGy) for OARs, while a 3 mm dose
grid size produced a variation of less than 1% (approximately 12 cGy) [88]. This suggests that below
a dose grid size of approximately 3 mm, the dosimetric dependence on dose grid size is negligible.
However, the position of the dose grid also appears to have some effect on the results. Chung et al.
performed a phantom study, in which they prescribed 5,400 cGy to shallow and deep targets, using
Pinnacle. They found that dose grid size had a significant effect on the prescribed dose to the
PTV [89]. When this error is combined with the variation introduced by changing the dose grid
resolution, the choice of dose grid parameters becomes significant. Even in this thesis, some dose
grid effects were observed, as seen in Section 3.1.2. While these effects may have been relatively
small compared to the overall trend, it still highlights the importance of consistency in dose grid size,
as a larger dose grid may have generated a slightly different trend.
In summary, the uncertainties present in calculating the maximum point dose for a volume are
significant. When this metric is then used for plan evaluation, it has the potential to be misused. If
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the planner or clinician does not appreciate the uncertainties inherent to the metric, they will be
more prone to misinterpretation of a borderline result.
4.1.2 Utility in treatment planning
Several modern TPS’s, including Raystation and Pinnacle, will place a ’warning’ flag on evaluation
metrics that are close to failure. The recommended course of action one should take upon seeing
these flags is often somewhat unclear, and is left to the discretion of the clinician, increasing the
potential for human error in clinical plans. Those with a proper appreciation of uncertainties may
view this as a recommendation to place extra restrictions on the dose to the affected volume. Others
may simply read the metric as a warning, and accept the result without considering the probability
of the actual patient dose exceeding the calculated value.
The author would like to propose an alternative solution: a confidence interval that could be
introduced to the maximum point dose for any volume. The interval type should be relatively
common - for example, one consisting of two standard deviations from the mean (95% confidence).
The size of the interval would primarily be a function of the dose registered, as well as the position
of the OAR relative to the treatment volume. If any OAR doses fell within one of these confidence
intervals for a particular DVH threshold, then a recommended action could be taken by the planner,
such as a preferential reduction of dose to that OAR. Of course, this would be a difficult solution to
implement. In order to quantify the size of these intervals, a robustness analysis would need to be
performed on a broader range of treatment errors than the ones covered in this thesis. The interval
size would also be accompanied by its own error, which would need to be negligible compared to the
interval size for this technique to be viable. The data density required for this degree of accurate
prediction of interval size would therefore be sizeable. In addition, the interval size would certainly
be a function of several other variables, such as linac type, treatment site, and beam energy, amongst
others. It would also be necessary to perform the robustness analysis using multiple dose grid
resolutions, in order to quantify their effect on the interval. In conclusion, this technique may not be
viable for implementation in an entire TPS, much less a standard clinical centre. However, this
shows just how much information is missing when one interprets the maximum point dose as an
evaluation metric.
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An alternative to the above solution would be to quantify the predicted change in NTCP values for
introduced errors. This would provide a metric that is more clearly understood by a broader
audience, as the NTCP for any particular OAR is simply a percentage value. Unfortunately, the
uncertainties inherent to NTCP calculations are even more significant than dosimetric uncertainties
due to the lack of clinical data available. (Additionally, the magnitude of the TCP uncertainties
must be, by definition, a function of the magnitude of the uncertainties in dosimetry.) Still, the end
result would be more readily interpreted if it were a simple NTCP percentage rather than an
uncertainty bracket.
A simpler alternative to using maximum point dose is a scaleable volume metric, such as V30 Gy
which was used for the chest wall in these experiments. The DVH already provides this functionality
inherently. This type of metric is determined from a number of voxels that is high enough to negate
the effect of both dose grid resolution and position. For instance, while an average dose of the entire
volume can be measured with this technique, the average dose of far smaller volumes can also be
measured, while still covering a large number of voxels. A compromise between using a point dose
metric and a larger volume-based metric can thus be achieved.
It should be noted that during the writing of this thesis, Auckland Hospital updated its DVH
metrics for conformal arc lung SABR plans to include both ’mandatory’ and ’optimal’ constraints,
based on international recommendations in trials such as CHISEL, RTOG 0915, and SAFRON
II [90–92]. This is at least a partial reflection of the uncertainties involved in treatment delivery,
although the decision of which constraint to use may still be open to interpretation.
4.2 Commissioning of MapPHAN
The angular dependence of MapCHECK inside MapPHAN was successfully reduced to levels similar
to those achieved by Jursinic et al. [75]. Since the MapCHECK model used in this thesis is different
to the ones used in their paper, the results aren’t directly comparable. However, the similarities
between the angular dependency trends are sufficient indication that the techniques used here to
minimise angular dependency could be applied to a broad variety of phantoms with planar (and
perhaps even non-planar) detector arrays.
84 Chapter 4. Discussion
4.2.1 Angular dependency of diodes and determination of density
overrides
Based on the results of this thesis, the recommendations that Sun Nuclear provide for commissioning
of MapPHAN appear inadequate for accurate QA of arc therapy. This conclusion has been reached
in other papers [75,76,93,94], although suggested alternatives to correct for this issue are scarce and
variable. The methods used in this thesis are most closely aligned with those utilised by Jursinic et
al. [75], based on the literature sampled.
A 10o gantry spacing was considered acceptable for these measurements, assuming that any
potential aliasing effects would be minimal, as this spacing is on par with measurements taken in the
literature. In addition, Jursinic et al. [75] took measurements using only the central diode, and
attained an angular dependency that was within 2%. The results in this thesis were taken using the
mean dose calculated to the central five diodes, making the assumption that the dose falloff over this
1 x 1 cm2 region would be approximately linear. This technique increased the statistical relevance of
the results, and was an appropriate surrogate for the central diode dose. However, it also provides a
more realistic assessment of the angular dependency of the phantom structure as a whole, rather
than analysing the dependency of the central diode alone, which has been performed multiple times
before. By analysing more than one diode simultaneously, the effect of systematic biases in the
dependency of the central diode were reduced.
The measurements taken in the central diode region (within 40 mm of the central diode column)
should be given priority in commissioning this device for lung SABR, for two reasons: the first being
the fact that 10 x 10 cm2 beams were used for the angular dependency measurements, meaning that
diodes at a distance ≥ 50 mm from the central diode were either in the buildup region or outside of
the central beam axis region for a high proportion of the measurements. The uncertainty in these
regions has been found to be significantly higher than for measurements in the central beam axis
region [87], which is reflected in the data here. Secondly, since the device was being commissioned
for the QA of lung SABR plans, it can be assumed that the maximum PTV size is below 8 cm in
width along its major axis, meaning that the high dose-gradient SABR-generated dose distributions
will fit within this central diode region. Because the SNC Patient software was configured to ignore
doses below a threshold of 10%, the only measurements that are truly relevant to the QA of lung
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SABR plans are those in close proximity to this central diode region. The caveat of this is that the
device will need to be re-commissioned before it can be used for the QA of treatment plans with
fields that extend beyond this central diode region.
By changing the density of the array region and measuring the ratio of calculated to measured dose
for other gantry angles, it became clear that the density of the array only had a significant effect
when the beam was passing through it at gantry angles from 80o to 100o, or from 260o to 280o,
where the effective thickness of the array relative to the beam axis was greatest. This meant that the
array density override could be calibrated relatively independently, using just these gantry angle
measurements to determine the most appropriate density to use.
It was decided to set the array density in such a way as to maximise alignment between the PDDs in
the central region of the array, while sacrificing alignment towards the edges, as can be seen in
Figure 3.11. This was permissible for multiple reasons. Firstly, when creating the QA plans, the
centre of the array was always aligned with the region of maximum dose - i.e. the region of the
target volume. For lung SABR, this volume is typically quite small, on the order of up to 5 cm.
Hence the region of the array requiring the highest degree of calibration accuracy was the central 5 x
5 cm2 portion which was going to be irradiated directly for each patient plan. The alignment of the
PDDs over this region was within 1% tolerance for G90 and G270 beams, indicating that there
would be no dosimetric disadvantage to aligning the PDDs in this way, when measuring in this
central array region. Secondly, the range of gantry angles where the disparity is highest remains
small compared to the entire range of angles used during a single treatment. The only gantry angles
that were significantly influenced by the disparity were G90 and G270.
To illustrate this, changing the array density in Raystation from 0.75 g cm-3 to 0.80 g cm-3 led to a
2.2% change in calculated dose to the central diodes when the beam was delivered at gantry 90o, but
only a 0.2% change in calculated dose at gantry 80o and 100o, and negligible difference for all other
gantry angles. Hence even if the density of the central section were assigned incorrectly, the effect
this would have had on the total calculated dose would have been relatively low. Considering the
fraction of the arc subtended by these affected angles, it can be assumed that the dosimetric errors
that would have been introduced as a result of this intervention will be relatively minor. There
would also have been minimal effect on the periphery of the array, where the dose received is of little
concern due to the limits placed on PTV size.
86 Chapter 4. Discussion
Standard deviation of dosimetric discrepancy as function of gantry angle
The standard deviation in dosimetric discrepancy for central axis diodes (see Figure 3.12) can be
interpreted as another measure of the agreement between the calculated and measured dose.
However, when compared to the mean discrepancy, this value provides a better indication of regions
where the density overrides applied are unfairly weighted towards increasing the dosimetric accuracy
for a particular subset of diodes. An example of this can be seen in Figure 3.11. The SD increases
significantly from 1.35% to 6.02% when all central axis diodes, rather than just the central nine
diodes, are included in the calculation. Most diode positions in Figure 3.12 show a similar - albeit
less significant - increase in SD, with some exceptions (for instance, at G200 and G210 for the
coronal MapPHAN). This highlights the fact that the density overrides applied during the angular
dependency measurements were chosen to validate measurements in the central diode region, and
may introduce dosimetric offsets to diodes closer to the phantom periphery. While some of the
increase in uncertainty can be attributed to out-of-field doses, this is clearly not a factor for beams
that pass parallel (or close to parallel) to the diode array. It is at these angles that the dosimetric
utility of the phantom is weakest. This should be kept in mind by the physicist during QA. If they
are delivering arc beams that are oriented primarily through the most affected range of gantry
angles, then they can expect to see greater dosimetric uncertainty in their final dose distribution.
The density overrides can’t account for the potential of each diode having its own individual angular
dependency curve, due to manufacturing differences between each diode. These differences are
probably a factor in the significant variation seen in some of the outlier diodes observed in Figure
3.12. However, it is difficult to determine to what extent these outliers were also a function of the
inaccurate application of density overrides for diodes at the periphery of the array. In essence,
having these diodes housed in a phantom makes it virtually impossible to isolate the individual
angular dependency characteristics of each diode. One would need to measure each diode’s
dependency in an external, isolated environment to observe the true variance of this effect.
Analysis of angular dependency in literature
The angular dependency trend observed in Figure 3.10 has been observed in several publications,
who report a maximum change in sensitivity of up to 25% as a function of the angle of
irradiation [54,74–76]. Li et al. performed an angular dependency analysis on the Sunpoint diode
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detectors used in ArcCHECK (identical in structure to those in MapCHECK 2) and plotted a graph
of the discrepancy between calculated and measured dose for a number of gantry angles and diodes.
The trends they found were similar in nature to the trends found here. In particular, the dip in
measured dose for beams delivered at G90 and G270, with the associated increase in measured dose
at gantry angles close to these cardinal angles, were both consistently observed. ArcCHECK houses
1386 diodes in a helical array, meaning that beams oriented at 90o and 270o to individual diodes
would not have been directly impeded by other diodes before reaching the diode which was
measuring the angular dependency curve. This confirms that the angular dependency observed is
mainly due to the structure of the diodes themselves, and not the fact that the diodes are arranged
in a planar array in MapCHECK 2. However, this almost certainly had some effect, as shown by the
more pronounced fluctuations in the regions of Figure 3.10 where the beam passes laterally through
the array.
Jursinic et al. state in their paper on angular dependencies in diodes that ”Low energy electrons are
backscattered at the interface of low and high atomic number materials, and this results in higher
diode sensitivity to photons that enter from the directions of the front and back surfaces of the
copper plate” [54]. In addition, the ’sandwich’-type construction of the array will likely produce
heightened diode response when a lower fraction of the cross-sectional beam is directly attenuated by
the array itself. Keeling et al. [74] found that this effect increased to a maximum potential
discrepancy of 37% for beams passing through the diode array at 90o and 270o. Hence the inherent
angular dependency of the diodes is likely compounded by the planar nature of the diode array,
which affects beams with a central axis that is parallel to the plane of the array.
It should also be noted that this effect is more pronounced for lower energy photons, and has a
greater dependence on field size for lower energy photons. This phenomenon was observed by
Keeling et al. [74], who compared the angular dependence of MapCHECK’s diode detectors in 6 MV
and 10 MV photon beams, for field sizes of 5 x 5 cm2 and 10 x 10 cm2. A smaller field size was
found to significantly increase the percent dose difference between measured and planned doses, with
the increase in discrepancy being approximately proportional to the initial dose discrepancy when
field size was decreased. The increase in discrepancy was also higher for 6 MV beams compared to
that for 10 MV beams. This can be explained by lower energy beams having higher backscatter rates
in media, resulting in an overresponse of the diodes to lower energy photons. Jursinic et al.
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discovered that removal of the copper plate found in these Suncheck diodes produced as much as a
6.4% decrease in the angular dependencies of the diodes, and suggested that they should not be used
for arc therapy QA [54].
In reality, stating the maximum angular dependence of the phantom as a single percentage is not a
fair assessment of the entire angular dependency profile. While the mean discrepancy for the central
diodes across all gantry angles is 0.28% for the coronal orientation and 0.39% for the sagittal
orientation, there are certain gantry angles for which the standard deviation or mean discrepancy
between measured and calculated dose (and sometimes both) is more significant. For instance, it can
be expected that beams delivered between 180o and 350o with the phantom in the sagittal
orientation can be expected to generate a mean discrepancy of 0.61% between calculated and
measured doses for the central diodes. The statistics appear worse when considering individual
diodes. For the same phantom orientation and beam, the mean discrepancy between calculated and
measured dose for the diode at -10 mm from the central diode would be 1.93%. While this remains
within the expected absolute dose tolerance of ± 3%, it is a concerning result, as these introduced
dosimetric biases may not be fully appreciated by the physicist performing QA on a plan with beams
predominantly in these angles. The assumption is made that the majority of plans are delivered with
beams that cover the entire range of gantry angles, and that the dose being delivered is spread out
evenly over the range of beam angles. In this way, the dosimetric imbalance generated at certain
gantry angles is rectified somewhat by opposing imbalances at other gantry angles. This is a
generalised solution that will not work for all plans, however.
In summary, the choice to optimize density overrides in Raystation to counter the angular
dependencies in MapCHECK was suitable for commissioning purposes. The aim was to assess the
angular dependency of the phantom in a more holistic manner than is seen in some of the literature.
Stating the angular dependency from the central diode alone doesn’t account for the fact that the
corrections made to reduce the dependency were specific to this region of the phantom. If the other
diodes were taken into account also, this would likely generate entirely different correctional values.
By taking into account the central five diodes during angular dependency measurements, as well as
looking at the dose to all diodes using SNC Patient software, both the inherent angular dependency
of the diodes and the shape of the phantom as a whole could be accounted for.
SNC Patient software includes the angular dependence uncertainty in their measurements for
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ArcCHECK diode measurements only, despite the fact that they designed the MapPHAN to be used
for measurement of arc therapy. Even so, their stated value for this uncertainty is 0.5% after angular
correction. This may be correct for ArcCHECK, but certainly not for MapCHECK. Even with the
assumption that beams will be delivered to the phantom in directions orthogonal to the diode plane,
the uncertainty still ranges up to ± 1% for beams within the ranges of G320-G40, and steadily
increases beyond that (see Figure 3.9).
4.3 Patient specific quality assurance measurements
4.3.1 MapCHECK dose calibration
The initial results acquired for PSQA exhibited poor absolute dosimetry. MapCHECK is calibrated
by delivering 100 MU of the desired beam energy to the centre of the phantom, with the diode plane
located at isocentre in a coronal orientation. The dose recorded by the central diode of the array is
then used as the calibration factor for calculating absolute dose in the remaining diodes. Initially,
calibration was performed with a 3 cm slab of solid water placed on top of the MapCHECK
phantom, as is convention at Auckland Hospital. Following calibration, MapCHECK was then
inserted into MapPHAN and positioned for measurements. This contributed a mean dosimetric error
of 2.0%, which had a significant effect on gamma pass rates.
A number of reasons for this discrepancy were posited, and various alterations were tested. A couple
of plans were delivered with a reduced control point spacing (i.e. a reduction from 4o to 3o per
control point), which had no significant effect on the dosimetry of the central diodes of the phantom.
This result was expected, as control point spacing has the greatest dosimetric effect on the periphery,
as can be seen in Figures 3.1 and 3.2, where the outline of the 40% isodose line can be observed. The
jagged nature of this line is a direct result of the dose from individual beamlets being calculated at
each control point. The isodose lines closer to the centre of the PTV are smoother due to the
merging of these spikes generated by individual control point beamlets.
Two alternative beam models were then used to calculate dose in Raystation. One of these was an
older version of the beam model which was not optimized for SABR delivery with smaller fields, and
thus did not improve results at all. A newer beam model with a unique method of modelling
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collimator scatter from the linac jaws and other beam modifiers was also tested. This beam model
slightly improved the absolute dosimetry of the most central diodes, but was found to reduce the
alignment between measured and calculated doses for the high gradient dose regions of the plan.
Ultimately it was decided to use the original beam model for this reason.
It was discovered that the experimental setup used for dose calibration had a significant effect on the
calibration value. An alternative dose calibration method was tested, with the phantom being
inserted into the MapPHAN prior to measurement, providing 5 cm of solid water buildup instead of
the usual 3 cm. Additionally, it provided additional backscatter due to the extra solid water placed
underneath MapCHECK. This setup generated a dose calibration factor that was, on average, 2.0%
higher than the factor generated by the use of 3 cm of solid water buildup. In order to correct the
measurements previously taken with the incorrect dose calibration method, this 2.0% correction
factor was retrospectively applied to the absolute recorded dose for the previously measured plans.
The reasons for this discrepancy remain somewhat unclear, as the modelling of the variable levels of
solid water in Raystation should, in theory, result in approximately identical dose calibration factors
for both setups.
The issue is conflicted by the fact that the solid water used for the MapPHAN was modelled at 1.02
g cm-3, which was shown to reduce the Raystation calculated dose to the central diode by 0.3% when
compared to calculations performed with a density override of 1.00 g cm-3. Because the density of
the MapPHAN was determined based on the angular dependency measurements, there is some
uncertainty in the accuracy of the density override of 1.02 g cm-3. This value is likely to be offset
from the true value in order to partially correct for the inherent angular dependencies of the diodes.
It is also possible that the presence of the solid water backing provides a significant addition of
backscatter that is detected by the central diode but not accounted for by Raystation, as the
collapsed cone algorithm in Raystation has been shown to model backscatter poorly [87]. The
presence of a hole in the posterior plastic backing of the phantom, located directly beneath the
central diode, would in theory increase the backscatter dose deposited in the central diode from the
posterior piece of solid water. The rate of backscatter from this solid water is likely to be higher
than that produced by the couch, which is lower in density with a decreased attenuation
cross-section that, in theory, will produce a lower rate of backscatter as a result. Hence the presence
of this piece of solid water is likely to have had a small effect on the dose calibration. In summary,
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this highlights the importance of using the same setup conditions for dose calibration and
measurement, if possible, as this prevents the possible addition of unaccounted factors.
Despite its issues, MapCHECK housed in MapPHAN has two key advantages as a QA device over
other diode array alternatives, such as ArcCHECK. It allows for measurement at more realistic
depths, thanks to the central location of the diodes housed within a thick casing of water-equivalent
media. By comparison, the ArcCHECK array provides what is essentially a fluence-based
measurement, with only a single point-dose taken at a realistic depth with the ionization chamber
insert. MapCHECK is also able to attain a higher resolution than ArcCHECK (0.5 cm vs 1 cm
resolution, since the helical arrangement of ArcCHECK’s diodes prevents simple overlapping of
measurements in the way that MapCHECK does).
4.4 Analysis of MapPHAN measurements
Kim et al. performed a sensitivity analysis of the gamma index method to MLC positioning errors in
SABR [65]. They found that 2%/1 mm, with passing rates of 80% and 90%, was the most suitable
gamma criteria for PSQA of VMAT SABR (a closely related technique to conformal arc SABR), out
of the gamma criteria of 1%/1 mm, 1.5%/1.5 mm, 1%/2 mm, 2%/1 mm and 2%/2 mm. The results
obtained here appear to confirm that 2%/1 mm with a threshold between 80% and 90% is an
appropriate set of criteria to use, especially if one wishes to improve detection of OAR threshold
failures. However, it would be useful to perform a more detailed analysis of the 5%/1 mm criteria
with PTV results included, in order to further confirm its suitability for gamma indexing. Despite
the lack of PTV analysis in this thesis, the detection accuracy of MapCHECK in MapPHAN to
introduced errors was observed to be similar to that seen in the literature [63–68]. However, it is
difficult to compare the ROC curve results obtained here with those obtained in the literature, due
to the plethora of different devices and error types that were introduced, as well as the variation in
gamma criteria between the two.
As it stands, gamma analysis has certain limitations when used as a metric for PSQA. Multiple
papers have criticized the ambiguity of the test. Depuydt et al. [95] highlighted the potential for
errors in the calculation for high dose gradient regions, especially when relative dose measurements
are used. In their paper, the authors highlight the potential for certain errors to be missed due to a
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lack of sensitivity to regions where a high density of points fail to meet the gamma criteria, while the
rest of the plan passes. If one were to improve the gamma algorithm to highlight particular regions
of interest where the potential for failure is greatest, then this would significantly improve the
algorithm’s QA benefits.
Several ROC analyses highlight the fact that the choice of parameters has a significant effect on the
rate of failure of plans. For the centres that do optimise these criteria, the optimal rate of plan
failure is commonly accepted as being 3%, regardless of the machine tolerances which are set in place
for each centre, meaning that certain centres will be stricter in their evaluation of individual plans
than others. For example, McKenzie et al. [96], during their substantive ROC curve analysis of
different IMRT PSQA techniques, referenced Dong et al. [97] for the prevalence of an unacceptable
plan - a study in which 751 plans were reviewed with ion chamber measurements. 97% of the IMRT
monitor unit calculations agreed to within 3.5% of the ion chamber measurements for the delivered
plans, in one of the largest studies of its kind that used a single TPS. However, this could be
considered a weakness of using the study results to infer the proper cutoff for PSQA pass rates, as it
was not a meta-analysis of multiple TPS’s, departments, and measurement techniques, although it
did sample plans from multiple treatment sites.
Additionally, the selection of optimal gamma analysis criteria based on ROC analysis will always
introduce some arbitrary bias towards either a more conservative or more liberal approach to QA.
Indeed, the authors of this paper found that determining the optimal gamma criteria based on the
3% threshold suggested by Dong et al. was essentially tantamount to performing a cost-weighting
exercise, in which the cost of misclassifying an unacceptable plan as acceptable was 1/16th of the
cost of misclassifying an acceptable plan as unacceptable [96]. The final result of this was increased
prioritization of efficiency over safety, since this cost analysis meant that passing an unacceptable
plan carried less risk. This goes against the standard ethos of the medical physicist, whose clinical
orientation is typically more conservative in the interest of ensuring absolute safety for patients,
where possible. However, the unfortunate reality is that a financial analysis of any therapeutic
system must set a limit on the minimal permissible efficiency of the system. Since it is much easier
to determine the cost of failing an acceptable plan (in terms of equipment and man-hours) than to
determine the cost of increased risk of passing an unacceptable plan, a slight bias towards efficiency
of QA is typically introduced into QA optimization [96].
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A significant disadvantage of 2D gamma analysis with MapPHAN is the lack of tissue-specific
information it provides. SNC Patient software does not provide users with the ability to export the
measured dose distribution, which would allow it to be overlaid on the CT slice from which it was
originally taken. This could be done to obtain a visual comparison of the measured and calculated
dose distributions with the CT dataset as a visual reference. This is not typically done, since it would
only provide data for one slice in the case of film and MapCHECK. However, this is a limitation
when trying to compare OAR and PTV doses between the measured and calculated treatment plans.
Granted, it would be virtually impossible to compare maximum point doses using a single slice of
dosimetric data (highlighting a limitation of PSQA in general), but by taking the ratio of the
measured and expected doses in a region aligned with a particular OAR on the CT dataset, one
could infer the expected measured dose at other regions in the organ. The main limitation of this
technique would be the rapid increase in uncertainty of interpolation accuracy as you move further
away from the plane of dose measurement. Hence as it stands, gamma analysis provides no
tissue-specific information, and is essentially a technique that focusses on PTV coverage, with very
little consideration given to OAR doses. As such, hot and cold spots in the delivered plan may be
ignored when the gamma pass rate is acceptable, especially when the pass rate is well within
tolerance levels, despite the possibility of potential OAR overdosing.
Implications of superior and inferior isocentre shift results
One unexpected result from Table 3.3 was the difference observed between superior and inferior
isocentre shift gamma results, as well as the difference between these shifted results and the gamma
results for the original plans. From a beam’s eye view perspective, the MapPHAN is an identical
shape irrespective of couch position when the couch is shifted 1 mm in the inferior or superior
direction. Granted, the diode position relative to the source will change when this occurs, but in
theory, this should only become an issue when no shifts are included in SNC Patient. The results in
Table 3.3 appear to confirm this. For example, consider the gamma results for the 1%/1 mm criteria
with the phantom in the sagittal orientation. The difference between the mean gamma pass rate for
merged results with isocentre shifts superior and inferior, when compared to the mean gamma pass
rate for the original plans, is statistically insignificant (90.3±2.7, 90.3±3.9, and 88.8±2.5,
respectively). This changes when looking at the same results, but with no SNC shifts applied
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(87.8±3.8, 72.7±7.5, and 81.0±9.2, respectively). Note that all error bars were calculated at the 1
SD level. For the second case, there is a statistically significant shift between the gamma pass rates
obtained for superior and inferior shifts. This can be attributed to the misalignment between the
dose distributions due to the shifts, which is going uncorrected without the application of automatic
shifts in SNC Patient. Similar discrepancies can be viewed throughout Table 3.3 for other criteria,
although in general, the discrepancies are smaller for different shift directions. This can be explained
by the fact that the phantom geometry changes relative to the source for all shift directions other
than superior or inferior shifts; therefore, the dose distribution will also change slightly as a
consequence, regardless of whether automatic shifts are included in SNC Patient.
The shifts performed by SNC were recorded throughout the experiment. The largest
automatically-performed shift observed was (2 mm, 2 mm) in the x and y directions. This
magnitude of positioning error would be remarkable if it were caused by the physicist setting up the
phantom for QA. There were several shifts of (2 mm, 1 mm) also observed, along with (1 mm, 1
mm) shifts, most of which could be partly attributed to the isocentre shifts being introduced to the
plans. The magnitude of these shifts seems to indicate that SNC Patient is overcorrecting for shifted
dosimetric profiles. One option for increasing the sensitivity of QA to geometric errors would be to
limit the maximum shift magnitude, perhaps to a vector of magnitude 2 mm in any direction. This
would be done in the expectation that the QA physicist is unlikely to set up a phantom with
positional error greater than this magnitude. Any machine errors of this magnitude or greater
should also be detected during regular linac QA, in theory, so this should hopefully not factor
significantly into the analysis.
The manual provided by Sun Nuclear for MapPHAN states the following: ’MapCHECK 2 with
MapPHAN-MC2 results indicate that 1 mm positioning errors are detectable, again demonstrating
the QA advantage of the high resolution diode detector.’ No further information is provided
regarding this statement. The results of this thesis are in clear opposition to this, especially when
automatic software corrections are introduced in SNC Patient, despite the fact that these results are
OAR specific. Stroom et al. [98] performed a robustness analysis on VMAT dose distributions with
introduced isocentre shift errors. Their study found that isocentre shifts as large as 3 mm only had
modest impacts on plan quality, with shifts of at least 1 - 2 mm being required to observe significant
dosimetric disparities in the PTV. The study methodology was similar to that performed here,
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suggesting that the errors introduced in this thesis were too small to provide data of clinical
significance. However, this does call into question the validity of the statement provided by Sun
Nuclear.
In summary, the evidence suggests that restrictions should be placed on shifts applied in SNC
Patient for gamma analysis. The inclusion of shifts has the effect of significantly decreasing the
detection of isocentre shift errors, and similar geometrical shifts. This is particularly the case for
superior and inferior shifts, which become virtually impossible to detect due to the identical
phantom geometry observed from a BEV perspective. This issue is unlikely to be unique to
MapPHAN, as there are several phantoms that appear symmetrical along the superior-inferior axis.
Additionally, the shifts used in this experiment, when applied, were significant, and were often
random, suggesting that SNC Patient was overcorrecting for shifted dosimetric profiles. While
further tests would need to be performed on other phantoms to confirm the results obtained here, it
appears likely that restriction of automated shifts would significantly improve QA sensitivity and
specificity to introduced geometrical errors.
4.4.1 Inter-group dosimetric error
A potential weakness of this study was the fact that measurements had to be taken on multiple days,
due to time constraints. For most of the subjects, isocentre shift results were taken at a different time
to the MLC and original results. Although dose was calibrated daily in order to negate the effect of
variation in output of the linac, it is probable that taking measurements on different days had a
significant effect on the magnitude of the dosimetric disparity between the planned and calculated
dose distributions. Because of this, any trends observed in the central diode disparity should be
isolated to the days on which they were taken. The validity of dose calibration is also reliant on the
assumption that the central diode reading is a consistently accurate summary of the diode readings
for the rest of the array. If the central diode itself exhibited any non-linearity over time, this would
have shifted the dose calibration for the entire array. This sort of discrepancy would be difficult to
detect without performing regular measurements comparing individual diodes on the array.
An example of the issues with performing dose calibrations on different days is as follows. If one
treats the MLC shift and isocentre shift results as separate measurement groups, the central diode
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disparity in the MLC results for Patient 2 may be compared directly to the disparity measured in
the original plan delivery (as these results were measured on the same day), but cannot be directly
compared to the disparity for isocentre results taken on a different day, as the variation in dose
calibration will have a significant effect on the inter-group dosimetric comparison. This also makes
the assumption that output fluctuations over the course of a day are relatively negligible.
4.4.2 Comparison of merged and unmerged MapCHECK
measurements
A comparison of the merged and unmerged MapCHECK results indicate that the gamma pass rate
is not significantly affected by increasing the resolution of measurement, with each combination of
gamma criteria and level of introduced error exhibiting overlap in their respective error ranges. This
implies that the merging of MapCHECK measurements is unnecessary for the QA of conformal arc
SABR. However, the merging of measurements for SABR plans is recommended, in order to obtain
more measurement points in high dose gradient regions. This in turn will make it easier to diagnose
the cause of QA failure if and when it arises.
4.5 ROC curve analysis
Greiner et al. [59] proposed a generic set of guidelines for interpreting the AUC for ROC curves,
using the following categories:
• AUC = 0.5 indicates that the test is non-informative;
• 0.5 < AUC ≤ 0.7 indicates a less accurate test;
• 0.7 < AUC ≤ 0.9 indicates a moderately accurate test;
• 0.9 < AUC < 1.0 indicates a highly accurate test;
• AUC = 1.0 indicates that the test is perfect.
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It should be remembered that only one or two individual classifiers will typically be utilised for
gamma analysis - i.e. individual points on the curves will be selected for use in PSQA. Hence, in this
case, the AUC is only a general indication of the accuracy of gamma criteria over the entire range of
possible thresholds. However, the AUC remains useful for determining which gamma criteria should
be selected for use in PSQA. The requisite threshold can be chosen after the gamma criteria
themselves have been selected, using the Youden index or a similar method. In this case, based
purely on the AUC values in Table 3.4, it appears that 5%/1 mm is the superior metric to use,
although there is probably not enough data to make a statistically significant case for this. More
realistically, one could suggest that a combination of 5%/1 mm and 1%/1 mm or 2%/1 mm criteria
be used to generate an accurate assessment of the validity of QA plans.
One key difference between the curves generated for MLC and isocentre shift errors is the
distribution of specific thresholds in ROC space for each set of gamma criteria. In general, the visible
thresholds (95, 90, 85, 80, 75, 70, 65 and 60) are shifted farther towards the North-East corner of
ROC space for the isocentre shift results. The effect can be seen most clearly when comparing the
results for 1%/1 mm and 2%/1 mm, between the MLC and isocentre shift charts. This can be
attributed to the introduction of MLC shifts having a greater dosimetric impact than the
introduction of 1 mm isocentre shifts, in general. The plans that were most affected dosimetrically
were in turn more likely to breach an OAR tolerance in Raystation. Since these plans contributed to
the ’Positives’ class as designated in Figure 2.6, they will have also contributed to the density of data
in the centre of the curve. This has the benefit of increasing the positioning accuracy of the
classifiers that are most clinically relevant, which are, ideally, closest to the point (0,1) in ROC space.
Another point of note is the variation in ROC data between orientations, for each respective set of
gamma criteria. For instance, the difference between the curves generated in coronal and sagittal
orientations for the 1%/1 mm criteria is significant, with the curve extending well below the line of
y = x for the coronal orientation - a trend that is not replicated in the sagittal orientation. Aside
from the aforementioned statistical variation in these trends, there are other potential reasons for
this discrepancy. The anisotropic nature of the dose distribution in Figure 3.2 means that, in theory,
certain orientations of the phantom will be advantageous in detecting dose fluctuations in a
particular axis.
For example, if the isocentre is shifted in the left-right direction on the patient couch, then placing
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the phantom in the coronal orientation will, in theory, allow the physicist to detect significant
dosimetric changes in this plane. (This assumes no shifts have been applied in SNC Patient
software.) However, placing the phantom in the sagittal orientation, with the simulated target
volume centred on the array, will prevent the detection of these sorts of fluctuations, as there is a
relatively wide range of positions in which the dose distribution will appear virtually identical on the
detector plane. This highlights the importance of performing QA with the detector array in multiple
axes, as well as multiple plane positions if possible.
4.5.1 Accuracy of ROC curve predictions
The Area Under Curve metric (AUC) has previously been criticized as a comparison metric, since its
accuracy can be misinterpreted when curves cross in ROC space. Hand [99] has declared that it uses
’different misclassification cost distributions for different classifiers. This means that using the AUC
is equivalent to using different metrics to evaluate different classification rules’. In this thesis, the
AUC was not an ideal metric for the analysis of gamma criteria, since the aim was to identify
optimal discrete classifiers - in other words, to identify the optimal pass rate threshold that should
be used for PSQA, in addition to the optimal gamma criteria that were used to generate the pass
rates themselves. Granted, it is useful to know which gamma criteria perform best along the
spectrum of discrete classifier points, but most of this information is made redundant as soon as one
discrete classifier is chosen by a clinic. This is a serious limitation of gamma analysis, and is one
reason why clinics should choose several gamma criteria for assessing plans. On the other hand, the
AUC could potentially be useful for comparing the diagnostic abilities of different phantoms, for
instance MapCHECK and ArcCHECK.
Flach and Wu [61] have posited a few options for repairing ROC curves with significant ’concavities’
that extend down towards the point (1,0) in ROC space, such as those seen in Figure 3.15. One can
repair these sections by simply mirroring the points in ROC space across the line from (0,0) to (1,1),
which would improve a worse-than-random prediction model to a better-than-random model. Even
by selecting diagonals between visibly optimal classifiers on the original ROC curve, and mirroring
individual concavities across these lines, one can improve minor concavities in regions where the
classifier model is performing poorly [61]. This is based on the assumption that the classifier being
modified has useful information about the data but is applying it incorrectly. However, this begs the
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question: can one be sure that the data is being incorrectly applied, rather than simply being worse
than random by chance? Since the ROC curve is ultimately a statistical measure, one can never be
absolutely certain. This must be considered in the case of isocentre shifts, where the curves are so
far removed from the diagonal ’guessing strategy’ that they seem quite implausible. A second check
of these results confirms their validity for these measurements, however. One would expect that
additional measurements would prove these results to be statistical aberrations, with the final result
being much closer to the line of random guessing. However, it cannot be denied that the sensitivity
of the phantom to isocentre shifts is less than desirable, as it stands.
It is difficult to verify how accurate the ROC curves are. Ideally a well-sampled ROC curve should
appear as smooth as possible, in a manner analogous to that of a normal distribution with a high
sample number. For ROC model specifiers that don’t provide a continuous prediction spectrum, any
vertical or horizontal lines almost certainly indicate a low sample number. This is because ROC
curve data is generated using a decision tree method, in which you can only generate a discrete
number of groups. The lack of sufficient data to generate statistically significant curves is a problem
if one wants to use these curves in a prescriptive fashion - for instance, if one wishes to determine the
optimal gamma criteria for a particular QA test. For the isocentre results obtained in this thesis, the
sample size is far too low to make anything other than a descriptive assessment of the accuracy of
certain gamma metrics, whereas for the MLC results, the sample size is probably high enough to
warrant a more precise, quantitative analysis of superior gamma metrics.
Correlation between gamma pass rates and AUC
Figure 4.1 shows the AUC as a function of mean gamma pass rate, for all levels of introduced errors,
based on Figure 3.17. The Pearson and Spearman correlation coefficients were calculated for each
dataset, as well as for the combined dataset of both error types, as seen in Table 4.1.
From the coefficients calculated, it can be concluded that there is no clear linear correlation between
AUC and mean gamma pass rate for individual tests. However, there are several corollaries to this.
Due to the low number of datapoints, a calculation of Pearson’s or Spearman’s correlation
coefficients would not provide a statistically significant assessment of the degree of correlation for
either dataset. The high p-values in Table 4.1 confirm this lack of statistical significance. In
addition, the combination of MLC and isocentre errors appears to form a quadratic trend, which
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Figure 4.1: AUC as a function of mean gamma pass rate, for all levels of introduced MLC and
isocentre shift errors.
cannot be fairly assessed by either Pearson’s or Spearman’s correlation coefficients as this is not a
monotonically increasing function. Hence a larger dataset is required for an accurate assessment of
any potential trends in either the MLC or isocentre shift error data, although an amalgamation of
the two datasets is theoretically possible. If this analysis were completed, it could potentially be
useful as a method for determining which mean gamma pass rate produces the greatest sensitivity
and specificity. This could be used as evidence for the selection of an optimal set of gamma criteria,
from which an ideal gamma threshold could be chosen via the Youden index.




Coefficient p-value Coefficient p-value Coefficient p-value
Pearson -0.05 0.87 0.20 0.54 -0.15 0.48
Spearman -0.10 0.76 0.16 0.61 -0.22 0.31
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4.6 Future work
This thesis has identified several potential areas of future work. In particular, the scope of the error
analyses performed in this thesis could be expanded significantly. The ROC analysis of MapPHAN
also needs substantial further investigation. These topics, and others, are discussed in the
subsections below.
4.6.1 Determination of optimal gamma thresholds
The ROC curves generated in this thesis are useful, in that they provide a general indication of the
best gamma criteria for PSQA of conformal arc plans. Generally, the performance of a single
classifier can be quantified using the Youden index, which provides advantages over the AUC in that
it is more specific to individual classifiers.
There are certain issues with this technique. Firstly, if one assumes that the original plan was
delivered perfectly, then the Youden index is being calculated purely based on MLC errors. This is
an unfair assessment of the high number of potential variations that could cause a QA plan to fail.
The number of datapoints is also an issue, especially for the isocentre shift results. Both of these
issues contribute to a further problem, which is the fact that the unbiased Youden index does not
take into account the preferred sensitivity and specificity that is required for QA. In the case of
radiotherapy, the cost of a false negative is high, as this could lead to a mistreatment of the patient.
However, this must be balanced to a certain extent by economic factors, such as the required patient
throughput for the centre. Hence using a particular set of criteria based purely on the Youden index
would probably not be the best solution for any particular centre. However, it could be used as a
potential starting point for further optimization.
It is normally the case that two sets of gamma criteria are used in tandem to detect treatment
errors. Based solely on a visual estimate of the Youden index calculated for MLC results in both
coronal and sagittal orientations, an appropriate combination of criteria for clinical use would be a
90% threshold with 2%/1 mm criteria, and a 95% threshold with 5%/1 mm criteria. This could be
used as a starting point for QA, with further optimization possible around these criteria, depending
on the specific needs of individual departments. This could be performed at multiple centres in order
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to obtain a broader dataset for analysis of the optimal criteria to use for QA. The choice of 1 mm
criteria is already appropriate for the high geometrical precision required of SABR treatments, which
is a useful result.
4.6.2 Relevance of analysis to other techniques
The lung was chosen as the region of interest for this study, as this was the only site at Auckland
Hospital being treated with SABR at the start of this project. This choice of location could be
considered a hinderance, as the number of OARs surrounding a PTV in this region is relatively low
compared to other regions of the body. In addition, the significant volume of low-density lung tissue
adjacent to the treatment region has a significant influence on the shape of dose distributions, which
is a unique feature of these treatments that isn’t replicated elsewhere in the body. Further studies
could investigate a variety of combinations of treatment sites and techniques, in order to determine
to what extent the conformal arc plans are representative of other arc therapies, in terms of plan
QA. In particular, an analysis of head and neck plans, in which there is a high density of OARs in
close proximity to the PTV, would provide a significant addition to the in silico analysis provided
here. Lung SABR plans in general have comparatively fewer OARs to analyse, making it difficult to
obtain a high density of data. However, if further work were to be done on lung SABR plans, a focus
on midline targets would be preferred in order to further quantify the effect of errors on heart and
spine doses.
VMAT has been shown to be a superior treatment to both 3D-CRT and DCAT for the treatment of
lung tumours using SABR, as it provides superior dose sparing to OARs [100]. As more departments
shift from DCAT and 3D-CRT to VMAT for delivery of SABR, the QA methods used to analyse this
technique will come under increased scrutiny. Repeating these experiments with patients treated
using VMAT would produce markedly different trends to those seen in Figures 3.5 to 3.8. Field size
is generally smaller in VMAT plans than in DCAT plans, with MLC leaves impinging on the
treatment volume itself, from a beam’s eye perspective. This means that introduced MLC errors
would generate more significant dosimetric fluctuations in the centre of the PTV rather than around
the periphery. This would likely reduce the maximum fluctuations in OAR doses seen in this thesis
for introduced MLC shifts. However, the higher field perimeter to field size ratio will increase the
significance of dosimetric fluctuations inside the PTV. It would be worthwhile to quantify this effect.
4.6. Future work 103
A similar trend to that seen in this thesis would probably be observed for the isocentre shift results,
although the overall fluctuations would again be less marked than for the introduced MLC errors.
Due to the general shift from DCAT to VMAT SABR in clinics worldwide, the demand for
high-resolution VMAT QA solutions is increasing. The experiments performed in this thesis prove
that MapCHECK in MapPHAN can provide sufficient resolution for high dose gradient
measurements. However, the phantom still needs to be validated for VMAT measurements, which
can generate sharper dose gradients than conformal arc treatments. The additional modulation of
gantry speed and dose rate, along with the increase in MLC modulation in terms of mean leaf
velocity, could prove to have significant effects on the sensitivity and specificity of the phantom. In
particular, the increased potential for interplay effect that MLC modulation in VMAT generates
could have a significant effect on these results.
However, it should be noted that a number of departments plan their SABR lung VMAT plans with
similar MLC field shapes and control point modulation to that seen in DCAT. This is done to reduce
the effects of interplay between breathing motion and MLC aperture position, which can be the
source of significant dosimetric uncertainties in the PTV [98,101]. For departments with SABR
VMAT treatments that are planned in this way, the results in this thesis are likely to be relevant to
their QA practices.
4.6.3 Dosimetric analysis
The introduction of class shift errors to treatment plans has the advantage of producing generally
linear dosimetric trends that are directly quantifiable. However, there are disadvantages to this
method. Realistically, one would expect to see MLC leaf errors with a random distribution of
negative and positive position errors relative to their expected position, since each MLC leaf is
calibrated and initialised individually. Additionally, conformal arc plans include a collimator twist of
10o or more. With collimator set to 0o, each leaf is aligned with the plane of gantry rotation,
meaning that individual leaf errors will also be aligned in one plane. Introduction of a small
collimator shift negates this effect. This means that the dosimetric effect of an MLC leaf
misalignment will be spread out over a broader range of tissues, rather than aligned in the plane of
the misaligned leaf. However, Depuydt et al. showed that even single leaf pair errors, where one pair
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of leaves fails during treatment delivery, can be picked up during gamma analysis [95]. Therefore,
the effect cannot be ignored entirely.
In particular, the effect of MLC class open errors are relevant to plans delivered on Elekta linacs.
The design of the MLC controllers on Elekta linacs (Elekta AB, Stockholm, Sweden) is such that the
leaf banks are calibrated using an individual reference leaf as a guide for an entire leaf bank. The
optically read-out position of this reference leaf is connected to the determined leaf position via a
linear calibration, using an offset and a gain parameter. These parameters are defined as ’major’ and
’minor’ values, whereby the major offset and gain parameters act on the entire MLC leaf bank, and
the minor parameters act on individual leaves [102]. Therefore, any errors in the calibration of the
reference leaf will propagate into the entire leaf bank. (This can be contrasted with other MLC’s
such as Varian’s Millenium MLC system, in which each leaf is calibrated individually [103].) The
introduction of a collimator twist to treatment plans will be unable to prevent this type of error from
having dosimetric effects as significant as the ones seen in this thesis, assuming the errors are of the
same magnitude. This should serve as justification for a rigorous QA routine that should be
performed on a daily basis (if not a per-treatment basis) for all MLC systems calibrated in this way.
One way to physically quantify the true effects of MLC position errors would be to generate plans
with MLC positions based on Dynalog files of actual treatments. These files contain a histogram of
the true MLC leaf position errors generated during treatments on Varian linacs. This would provide
more realistic dosimetric outcomes that could then be used for analysis of QA, although the dataset
required for a test like this would need to be substantial in order to obtain ROC curves with
sufficient statistical information.
4.6.4 Clinical implementation of MapPHAN
Only one phantom, with one type of dosimeter in a planar array structure, was analysed during this
study, which focussed only on plans with relatively small PTVs and high dose gradients. The
relevance of the results in this thesis to other QA methods is debatable. While it could be argued
that the MapCHECK phantom in MapPHAN, once properly commissioned, is a decent
representation of the type of results that could be obtained with any planar geometry-based QA
system (such as film), there is limited evidence in the literature to confirm this. One example that
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could be cited is the paper by McKenzie et al. [96], whose ROC analysis of multiple IMRT QA
techniques revealed similarities in the sensitivity and specificity of several planar (and non-planar)
QA techniques for multiple gamma analysis criteria, with techniques that included MapCHECK
coupled with SNC Patient software, EDR2 film with I’mRT software, and ArcCHECK with SNC
Patient software, which contains a helical diode array structure. However, this study was based on a
limited patient dataset, and a meta-analysis of multiple QA techniques for an extensive range of
treatment scenarios would provide a better indication of how accurately one phantom can represent
other QA techniques.
It would be worthwhile to see if these ROC curve patterns re-emerged with other phantom
geometries, such as the peripheral helical array geometry found in the ArcCHECK phantom. This
would provide an indication of whether these patterns are phantom independent, a conclusion that
can be tentatively derived from the comparison between merged and non-merged results in this
study. This prediction would be made based on the assumption that the analysis is
detector-resolution independent, as ArcCHECK has a minimum resolution of 1 cm spacing between
diodes, even with merged measurements.
The use of 1 mm isocentre shifts, while clinically relevant as they represented the limits of machine
QA tolerances at ADHB, limited the predictive accuracy of the ROC curves generated for
MapPHAN. The introduction of greater shifts, perhaps between 2-3 mm, would significantly increase
the density of data in the portion of the curve that contributes to the calculation of AUC. The
magnitude of these introduced errors would make these results more relevant to techniques that
don’t deliver ablative doses, but the data obtained would provide more accurate insights into the
value of using phantoms to detect positioning errors. In theory, it would also lend more credence to
the idea that applying automatic shifts in SNC Patient (and similar software) significantly reduces
the detection of isocentre shift errors, as the data obtained for this thesis are not entirely conclusive
on this point.
Work is currently being done to develop the ’Edgeless’ diode for radiotherapy [55]. This detector
purportedly achieves an angular dependence of less than ± 2%. These results were measured with
the diode housed in a cylindrical acrylic phantom, which was rotated with bidirectional accuracy of
0.25o beneath a static 10 x 10 cm2 6 MV X-ray beam delivered at G0 [55]. This technique eliminated
any dose uncertainties introduced by rotation of the gantry. The diode is fabricated using an ’active
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edge’ technology developed by VTT Technical Research Centre of Finland Micro and
Nanoelectronics, which uses ion implantation to activate the silicon wafer’s lateral junctions [104],
significantly reducing the diode’s dependence for lateral beams (i.e. at G90 and G270). This
manufacturing process is used in combination with ’drop in’ packaging technology used by the
Centre for Medical Radiation Physics [105]. The drop-in technology consists of a flexible carrier with
no high-Z materials, from which the detector die hangs. The lack of high-Z inhomogeneities means
that secondary electrons produced by the incoming X-ray beam can reach the active volume at an
approximately equal fluence rate from all directions. If successfully commissioned, this type of diode
would eliminate the necessity of approximating angular independence with density overrides. In the
case of MapCHECK, this would allow the full extent of the array to be utilised for PSQA, without
concern for increasing uncertainties towards the edges of the array.
Chapter 5
Conclusion
In this thesis, ROC curves were used to examine the efficacy of using MapPHAN for the QA of
DCAT lung SABR plans. A particular emphasis was placed on the phantom’s ability to detect
dosimetric errors in normal tissues.
MapCHECK with MapPHAN is a viable alternative to film for performing QA on DCAT lung
SABR plans. It provides sufficient resolution to measure in high dose-gradient regions, while
providing measurements at a depth close to the typical position of the target volume. The phantom
exhibits good sensitivity and specificity to introduced MLC errors, with results being comparable to
those seen in the literature. The poor accuracy of the phantom for detection of introduced isocentre
shift errors is expected, given that the magnitude of the errors we introduced (less than or equal to 1
mm) was low compared to the magnitude required for significant dosimetric effects (greater than 1
mm). However, restrictions could be placed on the shift magnitude automatically applied in SNC
patient, or shifts removed entirely, in order to improve the sensitivity of the phantom to these errors.
Increasing the resolution of the phantom by merging two measurements does not have a significant
effect on the phantom’s gamma pass rate (and hence sensitivity or specificity), but should be
performed if the physicist requires more detectors in high dose gradient regions.
Counter to manufacturer’s recommendations, the combination of MapCHECK housed in MapPHAN
does require extensive corrections to account for the inherent angular dependencies of its diodes.
Nonetheless, it can be commissioned to the point where absolute dosimetric measurements are
possible for a restricted section of the diode array (within 4 cm laterally of the central diode
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column). The application of variable density overrides to different sections of the phantom is a
feasible option for attaining the requisite level of accuracy, although the densities will need to be
optimised by each individual centre.
Based on the ROC curve analysis performed, a combination of 2%/1 mm with 90% threshold and
5%/1 mm with 95% threshold has been identified as an appropriate gamma analysis protocol for
conformal arc SABR treatments. These thresholds should be further optimized according to the
clinical and economical needs of each centre.
Chapter 6
Appendix
.1 Python code for class shift errors
The code shown below was used to introduce class shift errors to the original plans. These plans
were then imported into Raystation with the edited RTPlan files, and recalculated.
# Author : Nathan Henry , 2017
# This s c r i p t takes an RTPlan f i l e , and in t roduce s a c l a s s s h i f t e r r o r to
both MLC banks f o r each c o n t r o l point , b e f o r e gene ra t ing a new RTPlan
f i l e with the e d i t s inc luded .
from pydicom import dicomio
import os
import numpy as np
from sys import v e r s i o n i n f o
# This s e c t i o n t e s t s f o r python ve r s i on and ge t s input from user to
determine f i l ename
# Create boolean value f o r t e s t that Python major v e r s i o n > 2
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py3 = v e r s i o n i n f o [ 0 ] > 2
i f py3 :
f i l ename = input (” Enter f i l ename : ”)
e l s e :
f i l ename = raw input (” Enter f i l ename : ”)
# This s e c t i o n e d i t s dicom tag
ds = dicomio . r e a d f i l e ( f i l ename )
# This va lue r e p r e s e n t s the c l a s s l e a f p o s i t i o n e r r o r in mm f o r both MLC
banks
increment = 0 .2
# This s e c t i o n p u l l s out an array o f MLC p o s i t i o n va lue s and e d i t s them .
I t c y c l e s through a l l p o s s i b l e beams and c o n t r o l po in t s to s e l e c t the
maximum p o s s i b l e va lue f o r both , be f o r e e d i t i n g a l l c o n t r o l po in t s f o r
each beam .
beam num = 0
q = 0
whi le ( q == 0) :
t ry :
blah = ds [ 0 x300a , 0 x00b0 ] [ beam num ] [ 0 x300a , 0 x0111 ]
beam num = beam num + 1
except :
beam num = beam num − 1
q = 1
pr in t ( ’ Number o f beams = ’ )
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pr in t (beam num + 1)
f o r k in range (0 , beam num + 1) :
x = ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0 x0111 ] [ 0 ] [ 0 x300a , 0 x011a ] [ 2 ] [ 0 x300a , 0
x011c ]
q = 0
c t r l p o i n t = 0
whi le ( q == 0) :
t ry :
blay = ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0 x0111 ] [ c t r l p o i n t ] [ 0 x300a
, 0 x011a ]
c t r l p o i n t = c t r l p o i n t + 1
except :
c t r l p o i n t = c t r l p o i n t − 1
q = 1
pr in t ( ’ Current beam number = ’ )
p r i n t ( k+1)
p r in t ( ’ Number o f c o n t r o l po in t s f o r t h i s beam = ’ )
p r i n t ( c t r l p o i n t + 1)
# F i r s t c o n t r o l po int has ext ra 2 beam l i m i t i n g de v i c e s − jaws
p r in t ( ’\n ’ )
p r i n t ( ’Beam number = ’ )
p r i n t ( k + 1)
p r in t ( ’ Control po int = ’)
p r i n t (1 )
p r i n t ( ’ Or i g i na l MLC p o s i t i o n s = ’ )
p r i n t ( ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0 x0111 ] [ 0 ] [ 0 x300a , 0 x011a ] [ 2 ] [ 0 x300a
, 0 x011c ] )
p r i n t ( ’New MLC p o s i t i o n s = ’ )
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f o r i in range (0 , 60 ) :
ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0 x0111 ] [ 0 ] [ 0 x300a , 0 x011a ] [ 2 ] [ 0 x300a , 0
x011c ] . va lue [ i ] = ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0 x0111 ] [ 0 ] [ 0
x300a , 0 x011a ] [ 2 ] [ 0 x300a , 0 x011c ] . va lue [ i ]− increment
f o r j in range (60 ,120) :
ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0 x0111 ] [ 0 ] [ 0 x300a , 0 x011a ] [ 2 ] [ 0 x300a , 0
x011c ] . va lue [ j ] = ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0 x0111 ] [ 0 ] [ 0
x300a , 0 x011a ] [ 2 ] [ 0 x300a , 0 x011c ] . va lue [ j ]+ increment
p r in t ( ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0 x0111 ] [ 0 ] [ 0 x300a , 0 x011a ] [ 2 ] [ 0 x300a
, 0 x011c ] )
# I n s e r t new MLC p o s i t i o n s in to RTPlan f i l e
f o r m in range (1 , c t r l p o i n t +1) :
p r i n t ( ’\n ’ )
p r i n t ( ’Beam number = ’)
p r i n t ( k+1)
p r in t ( ’ Control po int = ’)
p r i n t (m+1)
p r in t ( ’ Or i g i na l MLC p o s i t i o n s = ’ )
p r i n t ( ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0 x0111 ] [m] [ 0 x300a , 0 x011a ] [ 0 ] [ 0
x300a , 0 x011c ] )
p r i n t ( ’New MLC p o s i t i o n s = ’ )
f o r i in range (0 , 60 ) :
ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0 x0111 ] [m] [ 0 x300a , 0 x011a ] [ 0 ] [ 0
x300a , 0 x011c ] . va lue [ i ] = ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0
x0111 ] [m] [ 0 x300a , 0 x011a ] [ 0 ] [ 0 x300a , 0 x011c ] . va lue [ i ]−
increment
f o r j in range (60 ,120) :
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ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0 x0111 ] [m] [ 0 x300a , 0 x011a ] [ 0 ] [ 0
x300a , 0 x011c ] . va lue [ j ] = ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0
x0111 ] [m] [ 0 x300a , 0 x011a ] [ 0 ] [ 0 x300a , 0 x011c ] . va lue [ j ]+
increment
p r in t ( ds [ 0 x300a , 0 x00b0 ] [ k ] [ 0 x300a , 0 x0111 ] [m] [ 0 x300a , 0 x011a ] [ 0 ] [ 0
x300a , 0 x011c ] )
# This s e c t i o n renames f i l e
##new f i lename = f i l ename . r e p l a c e ( ” . dcm” ,” e d i t e d . dcm”)
##
##p r i n t ( new f i lename )
##ds . s ave a s ( new f i lename )
# Al t e rna t i v e l y , t h i s s e c t i o n r e p l a c e s o ld RTPlan f i l e with ed i t ed f i l e
ds . s ave a s ( f i l ename )
p r in t (”Done”)
.2 Volumetric DVH parameter analysis of plans
The following figures show the increase in volume of OAR that would receive above their threshold
dose (as seen in Table 2.1) as a result of introduced MLC errors. The gradients are similar to those
used to generate Figure 3.3, except the DVH constraints used were volumetric rather than
point-dose based. Dashed lines indicate the thresholds at which the associated volumetric OAR
constraint would theoretically fail, if the potential MLC-induced volumetric errors were taken into
account. Due to the low number of datapoints available for each of these OARs, any attempt at
applying trends to the data would have been statistically irrelevant.
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Figure 1: Volumetric gradients generated in chest wall from introduction of MLC errors to
plans with a PTV dose of 48 Gy. Error bars quoted to within ± 2 SD.
Figure 2: Volumetric gradients generated in lungs from introduction of MLC errors to plans
with a PTV dose of 48 Gy. Error bars quoted to within ± 2 SD.
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Figure 3: Volumetric gradients generated in chest wall from introduction of MLC errors to
plans with a PTV dose of 60 Gy. Error bars quoted to within ± 2 SD.
Figure 4: Volumetric gradients generated in lungs from introduction of MLC errors to plans
with a PTV dose of 60 Gy. Error bars quoted to within ± 2 SD.
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Figure 5: Volumetric gradients generated in chest wall from introduction of isocentre shift
errors to plans with a PTV dose of 48 Gy. Error bars quoted to within ± 2 SD.
Figure 6: Volumetric gradients generated in lungs from introduction of isocentre shift errors to
plans with a PTV dose of 48 Gy. Error bars quoted to within ± 2 SD.
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Figure 7: Volumetric gradients generated in chest wall from introduction of isocentre shift
errors to plans with a PTV dose of 60 Gy. Error bars quoted to within ± 2 SD.
Figure 8: Volumetric gradients generated in lungs from introduction of isocentre shift errors to
plans with a PTV dose of 60 Gy. Error bars quoted to within ± 2 SD.
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.3 Angular dependency of MapCheck in MapPhan
Figure 9: Ratio of calculated/measured dose at all diode positions along central transverse
axis, for angular dependency measurements on MapCheck in coronal and sagittal orientations.
Trend line represents mean discrepancy for each gantry angle. Error bars represent 1 standard
deviation from the mean.
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.4 ROC curves for unmerged MapPhan results
(a)
(b)
Figure 10: ROC curves generated from unmerged MapPhan results with multiple gamma anal-
ysis criteria, for plans with introduced MLC shift errors delivered to MapPhan in both coronal
(top) and sagittal (bottom) orientations.
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(a)
(b)
Figure 11: ROC curves generated from unmerged MapPhan results with multiple gamma anal-
ysis criteria, for plans with introduced isocentre shift errors delivered to MapPhan in both
coronal (top) and sagittal (bottom) orientations.
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